[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 373
1. Wang H, Zhu Z, Xiao Y, Ma N, Li H, Wen Z: [The value of serum tumor marker CA125 and CEA in the diagonosis of non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Feb 20;11(1):97-100
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of serum tumor marker CA125 and CEA in the diagonosis of non-small cell lung cancer.].
  • BACKGROUND: Tumor marker cancer antigen 125(CA125) and carcinoembryonic antigen (CEA) all are the tumor markers found early.
  • It was reported that the positive rate of CEA was highly in adenocarcinoma, after being analyzed all the case reports of non-small cell lung cancer (NSCLC) in recent 3 years, it was found that positive rate of CA125 was much higher in NSCLC than that of literatures.
  • RESULTS: The levels of serum CA125 in NSCLC patients were significantly higher than that of patients with respiratory diseases and normal control (except mixed cell lung cancer) (P<0.0001).
  • The levels of serum CEA in adenocarcinoma and squamous patients were significantly higher than that of patients with respiratory diseases and normal control(P<0.0001).
  • The positive rates of CA125 were 92.3% in large-cell lung cancers, 80.2% in adenocarcinoma, 54.8% in squamous cancer, 50% in mixed cell lung cancer, respectively.
  • The positive rates of CEA were 67.4% in large-cell lung cancers, 25.8% in squamous cancer, 0 in adenocarcinoma and mixed cell lung cancer, respectively.
  • Combined measurement of CA125 and CEA positive rates was higher only in adenocarcinoma.
  • The positive rates of CA125 were 90.9% in advanced adenocarcinoma.
  • CONCLUSIONS: The positive rates of CA125 is higher than that of CEA in NSCLC patients, especially in large-cell lung cancers and advanced adenocarcinoma.
  • CA125 is more useful than CEA in diagnosis of NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727275.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Siegfried JM, Hershberger PA, Stabile LP: Estrogen receptor signaling in lung cancer. Semin Oncol; 2009 Dec;36(6):524-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor signaling in lung cancer.
  • Lung cancer has long been thought of as a cancer that mainly affects men, but over the past several decades, because of the high increase in tobacco use by women, there has been a corresponding dramatic increase in lung cancer among women.
  • Since 1998, lung cancer deaths in women have surpassed those caused by breast cancer in the United States.
  • Annual lung cancer deaths among US women currently surpass those caused by breast, ovarian, and cervical cancers combined.
  • Women are more likely than men to be diagnosed with adenocarcinoma and small cell carcinoma of the lung compared to squamous cell carcinoma, and never-smokers diagnosed with lung cancer are almost three times more likely to be female than male.
  • These observations in the population, coupled to the findings that both estrogen receptors (ERs) and aromatase, the enzyme that synthesizes 17beta-estradiol, are expressed by lung tumors, suggest a role for female steroid hormones in control of lung cancer growth.
  • Preclinical data and clinical data are increasingly emerging to support this concept, and to suggest that a local production of estrogen and expression of ERs occurs in lung tumors that arise in men as well as in women.
  • An additional protein that recognizes 17beta-estradiol with high affinity, GPR30, also is expressed in lung tumors at high levels and may be responsible for some of the proliferation signals induced by estrogen.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]
  • [Cites] FEBS Lett. 1996 Aug 19;392(1):49-53 [8769313.001]
  • [Cites] Nature. 1997 Oct 16;389(6652):753-8 [9338790.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Cell. 1998 Dec 23;95(7):927-37 [9875847.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3317-20 [10416585.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1459-70 [15735034.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1598-605 [15735050.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Chest. 2005 Mar;127(3):768-77 [15764756.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):372-81 [15862820.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6450-8 [16024650.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Oct;130(4):979-86 [16214508.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7280-7 [16243798.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4693-8 [16334162.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11287-91 [16357134.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):59-63 [16314616.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):337-44 [16391787.001]
  • [Cites] Mol Biol Cell. 2006 May;17(5):2125-37 [16495339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7165-9 [16636272.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):472-8 [17290054.001]
  • [Cites] Steroids. 2007 Feb;72(2):135-43 [17276470.001]
  • [Cites] Gynecol Endocrinol. 2007 Mar;23(3):131-7 [17454165.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10484-90 [17974992.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5785-92 [18089876.001]
  • [Cites] Lung Cancer. 2008 Jan;59(1):88-94 [17905466.001]
  • [Cites] Mol Endocrinol. 2008 Mar;22(3):609-22 [18048642.001]
  • [Cites] Cancer. 2008 Feb 1;112(3 Suppl):700-9 [18072256.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):157-74 [18164821.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] Oncology. 2007;73(5-6):305-10 [18493157.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4417-26 [18579664.001]
  • [Cites] Mol Cell Endocrinol. 2008 Aug 13;290(1-2):51-9 [18571833.001]
  • [Cites] J Cell Biochem. 2008 Dec 15;105(6):1342-51 [18846505.001]
  • [Cites] Mol Endocrinol. 2009 Feb;23(2):146-56 [19106194.001]
  • [Cites] Endocrinology. 2009 Mar;150(3):1112-21 [19008315.001]
  • [Cites] Ann N Y Acad Sci. 2009 Feb;1155:194-205 [19250205.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):51-9 [18701186.001]
  • [Cites] J Biol Chem. 2009 Apr 3;284(14):9540-8 [19189968.001]
  • [Cites] Steroids. 2009 Jun;74(6):489-97 [19428437.001]
  • [Cites] J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):102-9 [19460433.001]
  • [Cites] Lancet. 2009 Oct 10;374(9697):1243-51 [19767090.001]
  • [Cites] Jpn J Clin Oncol. 2009 Dec;39(12):829-32 [19692419.001]
  • [Cites] J Endocrinol. 2010 Feb;204(2):105-14 [19767412.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3175-82 [10866308.001]
  • [Cites] Mol Pharmacol. 2000 Sep;58(3):584-90 [10953052.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72 [11058619.001]
  • [Cites] Mol Endocrinol. 2001 Jul;15(7):1104-13 [11435611.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2465-8 [11923541.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2141-50 [11929836.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4562-74 [12959972.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8542-52 [14612399.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] Exp Eye Res. 2004 Apr;78(4):861-71 [15037120.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5 [15024130.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E1011-22 [14736707.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):689-701 [15171709.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):358-73 [15368362.001]
  • [Cites] Cancer. 1980 Dec 15;46(12 Suppl):2884-8 [7448733.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6126-33 [3664512.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Apr;74(4):879-83 [1548354.001]
  • [Cites] Genes Dev. 1993 Dec;7(12A):2431-45 [8253388.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5801-3 [7954403.001]
  • [Cites] Mol Cell Endocrinol. 1994 Aug;104(1):103-11 [7821701.001]
  • [Cites] Cancer Lett. 1995 Jan 6;88(1):1-5 [7850764.001]
  • (PMID = 19995644.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090440-09; United States / NCI NIH HHS / CA / P50 CA090440; United States / NCI NIH HHS / CA / CA090440-09S10006; United States / NCI NIH HHS / CA / P50 CA090440-09S10006; United States / NCI NIH HHS / CA / CA090440-09
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPER protein, human; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Aromatase
  • [Other-IDs] NLM/ NIHMS167495; NLM/ PMC2818861
  •  go-up   go-down


3. Huang J, Chen F, Wu Y, Yang J: [Expression and clinical significance of ADAM8 and CEA in serum of patients with non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Dec 20;11(6):789-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of ADAM8 and CEA in serum of patients with non-small cell lung cancer.].
  • BACKGROUND: Lung cancer is one of the most common cancers in the world, whose mortality is at the first place in all malignant tumors.
  • This study is to investigate the diagnostic value of ADAM8 and CEA in serum of non-small cell lung cancer patients.
  • RESULTS: The serum level of ADAM8 and CEA in group of NSCLC were both remarkably higher than those in lung benign lesions and normal controls (P <0.01), without significant difference between benign palmonary lesions and normal controls (P >0.05).
  • There was no significant difference between adenocarcinoma and squamous cell carcinoma in serum ADAM8 level (P >0.05).
  • The serum level of CEA in adenocarcinoma were significantly higher than that in squamous cell carcinoma (P <0.05).
  • The combined detection of ADAM8 and CEA could improve the sensitivity to 91.9%, but the specificity decreased to 75.0%.
  • CONCLUSIONS: The overexpression of ADAM8 in serum of NSCLC patients indicates that ADAM8 is related to the development of NSCLC; Combined detection of ADAM8 and CEA is helpful for the diagnosis of NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20797330.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Kim HT, Han JY, Lee DH, Chun JH, Lee HG, Lee JJ, Kim HY, Lee SY, Lee JS: A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. Cancer; 2006 Aug 15;107(4):799-805
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Irinotecan (1) and cisplatin (P) are active chemotherapy agents with clinical synergy in non-small-cell lung cancer (NSCLC).
  • Twenty-five patients had adenocarcinoma and 6 had squamous-cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826586.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Tian YX, Yang SY, Nan YD, Zhang W, Zhou B, Bu LN, Huo SF, Yu JK, Zheng S: [Use of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen differential proteins in lung adenocarcinoma and lung squamous carcinoma]. Zhonghua Yi Xue Za Zhi; 2008 Jan 15;88(3):145-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen differential proteins in lung adenocarcinoma and lung squamous carcinoma].
  • OBJECTIVE: To screen biomarkers for classification in lung adenocarcinoma and lung squamous carcinoma by using laser capture microdissection (LCM) and surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and support vector machine (SVM).
  • METHODS: Six specimens of lung adenocarcinoma tissues and seven specimens of lung squamous carcinoma tissues obtained during operation were made into frozen sections and stained by improved H-E solution.
  • About 1.2 x 10(5) of homogeneous adenocarcinoma cells and 1.4 x 10(5) of homogeneous lung squamous carcinoma cells were collected using LCM.
  • The expression levels of 6 proteins among them with the molecular weights of 3333, 3592, 3848, 5036, 5191, and 5211 respectively in the lung squamous cancer tissues were weaker than those in the adenocarcinoma tissues, and the expression levels of 4 proteins with the molecular weights of 2505, 4004, 4847, and 11 412 in the lung squamous carcinoma tissues were stronger than those in the adenocarcinoma tissues.
  • The expression of the protein with the molecular weight of 4847 in the squamous cancer was significantly stronger than that in the adenocarcinoma (p + 0.032).
  • A discriminatory pattern consisting of 3 proteins with the molecular weights of 4847, 11 412, and 3592 was established with a sensitivity of 100% and a specificity of 100% respectively in separating adenocarcinoma from squamous carcinoma.
  • CONCLUSION: There is a difference in protein component between adenocarcinoma and squamous carcinoma.
  • LCM combined with SELDI-TOF-MS help screen a biomarker pattern to distinguish lung adenocarcinoma from lung squamous carcinoma with high sensitivity and specificity.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Proteome / analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361807.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


6. Ring BZ, Seitz RS, Beck RA, Shasteen WJ, Soltermann A, Arbogast S, Robert F, Schreeder MT, Ross DT: A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol; 2009 Aug;22(8):1032-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
  • Malignant epithelial lung carcinoma can be subclassified by histology into several tumor types, including adenocarcinoma and squamous cell carcinoma.
  • The need for a uniform method of classifying lung carcinomas is growing as clinical trials reveal treatment and side effect differences associated with histological subtypes.
  • Diagnosis is primarily performed by morphological assessment.
  • These changes in how lung carcinomas are diagnosed and treated suggest that the development of improved molecular-based classification tools could improve patient management.
  • We used a 551-patient surgical specimen lung carcinoma retrospective cohort from a regional hospital to assess the association of a large number of proteins with histological type by immunohistochemistry.
  • Five of these antibodies, targeting the proteins TRIM29, CEACAM5, SLC7A5, MUC1, and CK5/6, were combined into one test using a weighted algorithm trained to discriminate adenocarcinoma from squamous cell carcinoma.
  • Antibody-based classification on 600 muM tissue array cores with the five-antibody test was compared to standard histological evaluation on surgical specimens in three independent lung carcinoma cohorts (combined population of 1111 patients).
  • Both the five-antibody test and TTF-1/TP63 panel had similarly low misclassification rates on the validation cohorts compared to morphological-based diagnosis (4.1 vs 3.5%).
  • The results of this study suggest the five-antibody test may have an immediate function in the clinic for helping pathologists distinguish lung carcinoma histological types.
  • [MeSH-major] Adenocarcinoma / classification. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / classification. Immunohistochemistry / methods. Lung Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430419.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CEACAM5 protein, human; 0 / Carcinoembryonic Antigen; 0 / DNA-Binding Proteins; 0 / GPI-Linked Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Large Neutral Amino Acid-Transporter 1; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / TP63 protein, human; 0 / TRIM29 protein, human; 0 / TTF1 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


7. Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y: The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol; 2010 Dec;5(12):1922-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
  • Conflicting data in many literatures were reported about the association between HER2 and poor prognosis in lung cancer.
  • In absence of significant quality difference between positive and negative studies, combined hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.
  • The pooled data showed that HER2 overexpression was a marker of poor prognosis in lung cancer.
  • HR was 1.48 (95% CI: 1.22-1.80) and 3.11 (95% CI: 2.26-4.28) for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) by immunohistochemistry (IHC) assay, respectively.
  • In other subgroup of squamous cell carcinoma tested by IHC, the combined HR was 0.87 (95% CI: 0.61-1.25), indicating that HER2 overexpression was not a prognostic factor for squamous cell carcinoma.
  • CONCLUSIONS: Although bias could be inevitable, this meta-analysis suggests that HER2 overexpression is a poor prognostic factor in lung cancer, especially for SCLC, adenocarcinoma, and early-stage NSCLC.
  • [MeSH-major] Lung Neoplasms / mortality. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / mortality. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mutation. Prognosis. Publication Bias

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21155183.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


8. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M: The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol; 2009 Dec;4(12):1568-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
  • INTRODUCTION: Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma.
  • Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens.
  • Using Cox multiple regression, factors for one model included treatment (PCb, GC, and VC), histology (squamous, adenocarcinoma, large cell, and other), gender, Eastern Cooperative Oncology Group performance status (0/1 and 2), stage (IIIB and IV), number of metastatic sites (< or = 1 and >1), and smoking history (yes or no).
  • In another model, histology was simply considered as squamous versus nonsquamous.
  • Subsequent pairwise comparisons of histology groups demonstrated a survival advantage for squamous cell carcinoma over adenocarcinoma (p = 0.0021).
  • Histology was prognostic for survival, with better outcomes associated with squamous cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009911.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Trani L, Myerson J, Ashley S, Young K, Sheri A, Hubner R, Puglisi M, Popat S, O'Brien ME: Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung Cancer; 2010 Nov;70(2):200-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
  • We have categorised patients treated with vinorelbine and gemcitabine based first line chemotherapy regimes for advanced NSCLC as either squamous or non-squamous, and also as either adenocarcinoma and non-adenocarcinoma, and compared outcome.
  • RESULTS: Neither univariate nor multivariate analysis suggested that there was a significant difference in the response rates for adenocarcinoma vs. non-adenocarcinoma or between squamous and non-squamous pathology.
  • There was no difference in PFS between adenocarcinoma and non-adenocarcinoma pathologies until 8 months (p = 0.98), and there was a statistically significant advantage in PFS for squamous vs. non-squamous pathologies (p = 0.04).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20227784.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


10. Galetta D, Rossi A, Pisconti S, Millaku A, Colucci G: Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question. Cancer Treat Rev; 2010 Nov;36 Suppl 3:S30-3
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
  • Lung cancer is the most common cancer worldwide with non-small cell lung cancer (NSCLC), including squamous carcinoma, adenocarcinoma and large cell carcinoma, accounting for about 85% of all lung cancer types with most of the patients presenting with advanced disease at the time of diagnosis.
  • After these cycles of treatment, non-progressing patients enter in the so called "watch and wait" period in which no further therapy is administered until there is disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / administration & dosage. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Molecular Targeted Therapy. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21129607.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glutamates; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


11. Harita S, Mizuta A, Kuyama S, Kikuchi T: Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only. Int J Clin Oncol; 2005 Feb;10(1):63-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.
  • We report two patients with non-small-cell lung cancer (NSCLC) with concomitant metastases to the brain only who received chemotherapy with concurrent radiotherapy for the thoracic disease and brain disease, resulting in long-term survival.
  • One patient was a 56-year-old woman who was diagnosed as having adenocarcinoma and showed T2N1 thoracic disease; the other patient was a 57-year-old man diagnosed with squamous cell carcinoma who had T1N3 thoracic disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Taxoids / administration & dosage


12. Kosacka M, Korzeniewska A, Jankowska R: [The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report]. Pol Merkur Lekarski; 2010 Feb;28(164):117-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report].
  • Lung cancer is a leading cause of cancer death in the majority of developed countries and in Poland.
  • THE AIM of this study was to evaluate the prognostic significance of cyclin B1 expression in primary, resected stage I-IIIA non-small cell lung cancer.
  • The prognostic values of cyclin B1 expression were presented in all examined patients and in patients with squamous cell lung cancer, adenocarcinoma and separately in every stage of disease.
  • CONCLUSION: In examined groups we did not reveal neither the prognostic value of cyclin B1 expression in patients with resected nonsmall cell lung cancer nor the correlations between cyclin B1 expression and neoadjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Cyclin B1 / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20369739.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin B1
  •  go-up   go-down


13. Liang ZY, Zeng X, Zhang J, Wu SF, Gao J, Liu TH: [Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):654-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma].
  • OBJECTIVE: To investigate EGFR mutations and gene copy number status in non-small cell lung carcinomas in the Chinese patients.
  • METHODS: Using formalin fixed and paraffin embedded tissue samples, EGFR mutations were investigated in 290 cases of non-small cell lung carcinomas by microdissection and scorpions amplification refractory mutation system.
  • Furthermore, the relationship between EGFR mutations and gene copy number, and the relationship between EGFR gene status and clinicopathological variables of non-small cell lung carcinoma were analyzed.
  • The mutation rates in adenocarcinoma, large cell carcinoma and squamous carcinoma were 48.4%, 16.7% and 0, respectively.
  • FISH positive rates in adenocarcinoma, large cell carcinoma and squamous carcinoma were 52.1%, 75.0% and 11.1%, respectively.
  • Therefore, EGFR mutations mainly occurred in the adenocarcinoma, and was significantly correlated with EGFR high copy number.
  • CONCLUSIONS: There are higher EGFR mutation rate and FISH positive rate in non-small cell lung carcinoma in Chinese patients.
  • Combined analysis of EGFR mutation and gene copy number by FISH may provide a superior approach in selecting patients who may benefit anti-EGFR target therapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Dosage. Genes, erbB-1. Genetic Diseases, Inborn. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094482.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


14. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC: Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer; 2006 Mar;51(3):303-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
  • PURPOSE: The cyclin D1 (CCND1) A870G gene polymorphism is linked to the outcome in patients with resectable non-small cell lung cancer (NSCLC).
  • Here, we investigated the impact of this polymorphism on smoking-induced cancer risk and clinical outcome in patients with NSCLC stages I-IV.
  • RESULTS: Patient characteristics were: 70% male, 77% smokers, 43% adenocarcinoma, and 27% squamous cell carcinoma.
  • Median age at diagnosis was 60 years and median survival was 13 months.
  • CONCLUSION: Evidence was obtained that the CCND1 A870G gene polymorphism modulates smoking-induced lung cancer risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Cyclin D1 / genetics. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Smoking / adverse effects


15. Meng YH, Yu JY, Lu YL, Zhu YJ, Zhang JQ, Ning HY, Hu M, Liu X, Kang XL, Duan W: [Expression of PAR-1 in human lung carcinoma and its relationship with tumor metastatic potential]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):24-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAR-1 in human lung carcinoma and its relationship with tumor metastatic potential].
  • OBJECTIVE: To explore the correlation between expression of PAR-1 and metastasis of human lung carcinoma.
  • METHODS: Expression levels of PAR-1 were examined in surgically resected lung carcinoma specimens and corresponding lymph nodes by RT-PCR and immunohistochemistry, combined with morphometric methodology and clinicopathologic profiles.
  • RESULTS: Strong PAR-1 staining was detected in the periphery of carcinoma nests, adenocarcinomatous emboli, foci of atypical adenomatous hyperplasia adjacent to the adenocarcinoma and atypical proliferation of duct epithelium of bronchial mucous glands.
  • Morphometric study demonstrated that there were significant differences of PAR-1 protein expression levels between tumors with metastatic and those without, primary and metastatic carcinomas, primary carcinomas and benign lung tissues adjacent to the carcinoma.
  • The positive rate of PAR-1 mRNA expression in the metastatic group was significantly higher than that of the non-metastatic group (78.3%, 18/23 v.s. 38.5%, 5/13).
  • CONCLUSION: PAR-1 expression may play an important role in determining the malignant phenotypes of lung cancers and significantly contribute to their initiation, progression and metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Receptor, PAR-1 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608645.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


16. Takahashi T, Yamamoto N, Murakami H, Ohe Y, Kunitoh H, Nokihara H, Koshiji M, Tamura T: A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):2572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC).
  • Pre-clinical data shows Enz's synergistic activity with Pem in many cancer cell lines including NSCLC.
  • This phase 1 study is to evaluate the safety, pharmacokinetics (PK), and clinical activity of two schedules of Enz combined with Pem in patients (pts) with previously treated advanced NSCLC.
  • RESULTS: 12 pts (8 males, 4 females; ECOG PS 0-1) with median age of 62 (49 - 74) were enrolled into this study and completed safety evaluation for cycle 1: 8 pts with adenocarcinoma, 3 pts with squamous cell carcinoma, and one with other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kshivets O: Lung cancer prediction: Phase transitions and cell ratio factors. J Clin Oncol; 2009 May 20;27(15_suppl):e22170

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer prediction: Phase transitions and cell ratio factors.
  • : e22170 Background: Search of precise prognostic factors for non-small lung cancer (LC) patients (LCP) was realized.
  • METHODS: In trial (1985-2008) the data of consecutive 490 LCP after complete resections R0 (age=56.7±8 years; m=439, f=51; tumor diameter: D=4.5±2.1 cm; pneumonectomies=206, lobectomies=284, combined procedures with resection of pericardium, atrium, aorta, VCS, carina, diaphragm, ribs=130; squamous=308, adenocarcinoma=147, large cell=35; T1=143, T2=217, T3=107, T4=23; N0=282, N1=115, N2=93; G1=114, G2=140, G3=236; early LC: LC till 2 cm in D with N0=58, invasive LC=432) was reviewed.
  • Variables selected for 5-year survival (5YS) study were input levels of blood cell subpopulations, TNMG, D.
  • Cox modeling displayed that 5YS significantly depended on: phase transition (PT) in terms of synergetics "early-invasive LC", PT N0-N12, histology, G1-3, cell ratio factors: ratio between the total populations of leucocytes, lymphocytes, neutrophils and LC cells (P=0.000-0.044).
  • 3) cell ratio factors;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963703.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, Watanabe N, Sakamoto J, Aoe M, Date H: A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses. J Clin Oncol; 2009 May 20;27(15_suppl):7560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses.
  • Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies.
  • The median survival time of A and B arms combined was 4.1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U: Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e19089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • : e19089 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel or cisplatin-gemcitabine.
  • METHODS: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression.
  • P characteristics were: male 66.7%; median age 57 years (range 41-74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1.
  • Most common grade 3/4 non hematological toxicities were: vomiting (1p gr.
  • CONCLUSIONS: This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lerouge D, Gervais R, Dansin E, Dujon C, Chouaid C, Riviere A, Precheur-Agulhon B, Piolat V, Zalcman G, Lartigau E: A fractionated schedule of oral vinorelbine (NVBo) with cisplatin (CDDP) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC): Safety and efficacy results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):7539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fractionated schedule of oral vinorelbine (NVBo) with cisplatin (CDDP) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC): Safety and efficacy results of a phase II trial.
  • METHODS: Non operable stage IIIA-IIIB NSCLC patients (pts) received an induction CT of 2 cycles of NVBiv 25 mg/m<sup>2</sup> + CDDP 80 mg/m<sup>2</sup> on D1 and NVBo 60mg/m<sup>2</sup> on D8 every 3 weeks.
  • Non progressive pts received 2 additional cycles of fixed dose NVBo of 20 mg on D1, D3 and D5, + CDDP 80 mg/m<sup>2</sup> on D1 every 3 weeks, combined with a conformal RT at 66 Gy.
  • RESULTS: Between October 05 and May 08, 70 pts were enrolled (68 evaluable for the safety, 64 for response) : 28% stage IIIA, 72% IIIB; 44 % squamous, 30 % adenocarcinoma; 85% male; median age 61 years (range 41;73); median KPS 90%.
  • This new scheme offers a well tolerated and efficient therapeutic option in the treatment of non operable IIIA-IIIB NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J: Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
  • : e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with advanced NSCLC other than predominantly squamous cell histology.
  • B has been shown to improve progression free survival (PFS) and overall survival (OS) when combined with cisplatin/gemcitabine and carboplatin/paclitaxel, respectively.
  • METHODS: Eligibility criteria: chemo- naïve, stage IIIB wet or IV, non-squamous NSCLC, PS 0-1, no brain metastases and no history of gross hemoptysis.
  • RESULTS: 50 p were enrolled (enrollment completed): 24% female, median age 60 (36-74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 92%.
  • CONCLUSIONS: Treatment with C, D and B, followed by maintenance B in 1<sup>st</sup> line of advanced non-squamous NSCLC shows an acceptable toxicity profile and promising efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Katsuragi N, Shiraishi Y, Kita H, Toishi M, Onda T, Tanaka S: [Locally advanced non-small cell lung cancer completely resected after induction therapy]. Kyobu Geka; 2008 Jan;61(1):9-14
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced non-small cell lung cancer completely resected after induction therapy].
  • We analyzed 8 patients with unresectable locally advanced non-small cell lung cancer who responded to chemotherapy or chemoradiotherapy and underwent complete resection between June 2003 and June 2005.
  • Histological subtypes included adenocarcinoma in 4 patients and squamous cell carcinoma in 4 patients.
  • 0-2, 27 (23) for pN0, 13 (9) for pN1-3, 31 (27) for chemoradiotherapy, 16 (13) for chemotherapy, 24 (21) for adenocarcinoma, and 15 (11) for squamous cell carcinoma.
  • Multimodality treatment, including surgery, is beneficial for patients with unresectable locally advanced non-small cell lung cancer who respond to chemotherapy or chemoradiotherapy, especially those patients with ycN0 or pN0.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186266.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A: In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res; 2005;15(1):39-48
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
  • The mechanism of action may involve inhibition of histone deacetylation and cell cycle arrest.
  • We studied the action of CI-994 on two non-small cell lung cancer (NSCLC) cell lines: A-549 (adenocarcinoma) and LX-1 (squamous cell carcinoma).
  • A concentration-dependent cell survival inhibition was observed, with an IC50 at 80 microM.
  • The effect of CI-994, as demonstrated by recovery experiments, was cytostatic and seemed to be superimposable in both cell lines.
  • Cytofluorimetric analysis to assess cell cycle perturbation and apoptosis was performed after 24 h of treatment, indicating a cell block with concomitant increase at G0/G1 phase, a reduction at S phase level at 20, 40, 80, and 160 microM, and apoptosis at the higher concentration (160 microM).
  • When CI-994 was combined with antineoplastic agents commonly used in NSCLC management, a marked synergism of action (R = 1.8, R = 1.5) was observed between CI-994 (40 microM) and gemcitabine (0.01 microM) at 48 and 72 h of treatment.
  • CI-994 showed no radiopotentiating effects, when combined with 100, 200, or 400 cGy irradiation.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Cell Cycle / drug effects. Lung Neoplasms / pathology. Phenylenediamines / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Survival. Dose-Response Relationship, Drug. Drug Interactions. Humans. Taxoids / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839304.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Phenylenediamines; 0 / Taxoids; 112522-64-2 / acetyldinaline; 15H5577CQD / docetaxel
  •  go-up   go-down


24. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol; 2005 Aug 1;23(22):4999-5006
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.
  • PURPOSE: Recent clinical trials have shown the efficacy of platinum-based adjuvant chemotherapy for completely resected non-small-cell lung cancer (NSCLC).
  • RESULTS: Of 2,003 eligible patients, most (98.8%) had squamous cell carcinoma or adenocarcinoma, and most had stage I disease; the tumor classification was T1 in 1,308 (65.3%), T2 in 674 (33.6%), and the nodal status was N0 in 1,923 (96.0%).
  • CONCLUSION: This meta-analysis showed that postoperative adjuvant chemotherapy with UFT was associated with improved 5- and 7-year survival in a Japanese patient population composed primarily of stage I adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051951.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur
  •  go-up   go-down


25. Nassar H, Albores-Saavedra J, Klimstra DS: High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol; 2005 May;29(5):588-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases.
  • We describe the clinical and pathologic features of 14 cases of high-grade neuroendocrine carcinoma (HGNEC) of the ampulla of Vater classified according to WHO classification of lung tumors into small cell carcinoma (SCC, 6 cases) and large cell neuroendocrine carcinoma (LCNEC, 8 cases) types.
  • Two HGNECs were combined with a conventional adenocarcinoma and another with a squamous cell carcinoma component.
  • The association with adenoma and or conventional adenocarcinoma components may suggest a common pathway in the initial carcinogenesis of these two types of tumors.
  • Thus, there are differences in the molecular phenotypes of these two types of ampullary carcinoma, supporting the distinction of poorly differentiated carcinomas with a neuroendocrine phenotype from those without.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma, Neuroendocrine / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832081.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK, Alpha Oncology Research Network: A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer; 2010 Dec;70(3):340-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
  • PURPOSE: Three phase III trials have shown pemetrexed to be associated with improved clinical outcomes among patients with adenocarcinoma and large cell histology compared with patients with squamous histology in advanced non-small cell lung cancer (NSCLC).
  • RESULTS: 202 patients (17.8%) had squamous, 555 (48.9%) had adenocarcinoma, 45 (4.0%) had large cell, and 333 (29.3%) had another histologic type.
  • The overall response rate for squamous patients was greater than non-squamous (35.1% versus 27.8%, P=0.04).
  • Median survival (9.5 months for squamous and 8.3 months for non-squamous) and median time to progression (5.0 months for squamous and 4.4 months for non-squamous) did not significantly vary by histologic group.
  • For squamous histology, median survival was 6.6 months for GCb, 10.2 months for GP, and 10.3 months for PCb.
  • For non-squamous disease, median survival was 8.2 months for GCb, 8.4 months for GP, and 8.3 months for PCb.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ireland Ltd.
  • (PMID = 20347506.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00054392
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, Goldin LR, Wacholder S, Welch R, Burdette L, Chanock SJ, Bertazzi PA, Tucker MA, Caporaso NE, Chatterjee N, Bergen AW, Landi MT: Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One; 2009 May 21;4(5):e5652
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression.
  • Polymorphisms in genes coding for enzymes that activate tobacco lung carcinogens may generate inter-individual differences in lung cancer risk.
  • We analyzed 25 SNPs (some previously untested) in 2101 primary lung cancer cases and 2120 population controls from the Environment And Genetics in Lung cancer Etiology (EAGLE) study from six phase I metabolic genes, including cytochrome P450s, microsomal epoxide hydrolase, and myeloperoxidase.
  • We evaluated the main genotype effects and genotype-smoking interactions in lung cancer risk overall and in the major histology subtypes.
  • We tested the combined effect of multiple SNPs on lung cancer risk and on gene expression.
  • Two haplotypes in EPHX1 were significantly associated with lung cancer risk in the overall population.
  • In addition, CYP1B1 and CYP2A6 polymorphisms were inversely associated with adenocarcinoma and squamous cell carcinoma risk, respectively.
  • Moreover, the association between CYP1A1 rs2606345 genotype and lung cancer was significantly modified by intensity of cigarette smoking, suggesting an underlying dose-response mechanism.
  • Results were supported by differential gene expression in non-tumor lung tissue samples with down-regulation of CYP1A1 in never smokers and up-regulation in smokers from CYP1A1/A2 SNPs.
  • Our findings emphasize the necessity of post-GWAS fine mapping and SNP functional assessment to further elucidate cancer risk associations.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2005 Apr 28;221(2):185-90 [15808404.001]
  • [Cites] Biochim Biophys Acta. 1983 Dec 29;695(3-4):251-70 [6418203.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5105-11 [15958554.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):306-10 [16176798.001]
  • [Cites] Epidemiology. 2006 Jan;17(1):89-99 [16357600.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):102-8 [16005144.001]
  • [Cites] Mol Pharmacol. 2006 Jun;69(6):1924-30 [16505155.001]
  • [Cites] Clin Pharmacol Ther. 2006 Sep;80(3):282-97 [16952495.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):255-62 [17174438.001]
  • [Cites] Int J Epidemiol. 2007 Feb;36(1):236-41 [17510079.001]
  • [Cites] Lung Cancer. 2007 Jul;57(1):1-25 [17337085.001]
  • [Cites] Future Oncol. 2007 Dec;3(6):617-27 [18041914.001]
  • [Cites] Carcinogenesis. 1998 Feb;19(2):291-8 [9498279.001]
  • [Cites] Carcinogenesis. 1998 Mar;19(3):387-93 [9525271.001]
  • [Cites] Nature. 1998 Jun 25;393(6687):750 [9655391.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1847-53 [9806168.001]
  • [Cites] Lancet. 1999 Mar 13;353(9156):898-9 [10093988.001]
  • [Cites] Toxicology. 1999 Mar 1;133(1):1-33 [10413191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):405-13 [18268125.001]
  • [Cites] Mutat Res. 2008 Mar 1;639(1-2):1-10 [18082227.001]
  • [Cites] PLoS One. 2008;3(2):e1651 [18297132.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):633-7 [18385738.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):638-42 [18385739.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1164-9 [18258609.001]
  • [Cites] BMC Public Health. 2008;8:203 [18538025.001]
  • [Cites] Mutat Res. 2008 Aug 25;643(1-2):4-10 [18573508.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 5;100(21):1552-6 [18957677.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1407-9 [18978787.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1404-6 [18978790.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):187-93 [18571762.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S7-11 [10582132.001]
  • [Cites] Pharmacogenetics. 2000 Feb;10(1):25-33 [10739169.001]
  • [Cites] Curr Opin Oncol. 2000 Mar;12(2):143-8 [10750726.001]
  • [Cites] Pharmacogenetics. 2000 Mar;10(2):105-14 [10761998.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3440-4 [10910054.001]
  • [Cites] Respir Med. 2000 Jun;94(6):564-8 [10921760.001]
  • [Cites] Chem Biol Interact. 2000 Dec 1;129(1-2):41-59 [11154734.001]
  • [Cites] Chem Res Toxicol. 2001 Jul;14(7):767-90 [11453723.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):155-62 [11597790.001]
  • [Cites] Histochem J. 2001 Jun;33(6):329-36 [11758809.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):890-4 [12223434.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(15):5194-8 [2991910.001]
  • [Cites] Carcinogenesis. 1991 Mar;12(3):521-4 [1849053.001]
  • [Cites] Environ Health Perspect. 1992 Nov;98:69-74 [1486865.001]
  • [Cites] Pharmacogenetics. 1991 Oct;1(1):20-5 [1726950.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):421-8 [7516776.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4965-9 [8895751.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1550-4 [12496042.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1555-9 [12496043.001]
  • [Cites] Carcinogenesis. 2002 Dec;23(12):1969-77 [12507920.001]
  • [Cites] Cancer Causes Control. 2003 May;14(4):339-46 [12846365.001]
  • [Cites] Biochim Biophys Acta. 2003 Jul 30;1638(3):208-16 [12878321.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6002-11 [14676126.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):1-6 [14720319.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):828-33 [15159316.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23847-50 [15028720.001]
  • [Cites] Xenobiotica. 1973 May;3(5):305-40 [4584115.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):265-74 [15896461.001]
  • (PMID = 19479063.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / U01 DA020830; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  • [Other-IDs] NLM/ PMC2682568
  •  go-up   go-down


28. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II: Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res; 2010 Jan 1;16(1):34-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions.
  • PURPOSE: To identify the pattern of interleukin-1 receptor-associated kinase (IRAK-1) protein expression in non-small cell lung carcinoma (NSCLC) and corresponding preneoplastic lesions.
  • EXPERIMENTAL DESIGN: Archived tissue from NSCLC (adenocarcinoma and squamous cell carcinoma; n = 306) and adjacent bronchial epithelial specimens (n = 315) were analyzed for the immunohistochemical expression of IRAK-1, and the findings were correlated with patients' clinicopathologic features.
  • Squamous dysplasias had significantly higher cytoplasmic IRAK-1 expression than normal epithelium.
  • In adenocarcinoma, combined low level of expression of nuclear IRAK-1 and NF-kappaB correlated significantly with worse overall (HR, 2.485; P = 0.007) and recurrence-free (HR, 3.058; P = 0.006) survivals in stage I/II patients.
  • CONCLUSIONS: IRAK-1 is frequently expressed in NSCLC tissue specimens, and this expression is an early phenomenon in the sequential development of lung cancer.
  • IRAK-1 is a novel inflammation-related marker and a potential target for lung cancer chemopreventive strategies.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Jul 14;477(1-2):73-8 [10899313.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5904-12 [18836471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):71-6 [12559770.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):293-302 [12620219.001]
  • [Cites] Clin Lung Cancer. 2003 Jul;5(1):46-62 [14596704.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):2011-22 [15265936.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6693-7 [1323115.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Curr Opin Immunol. 1999 Feb;11(1):13-8 [10047546.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3468-74 [10416612.001]
  • [Cites] Gene. 2004 Dec 8;343(1):191-201 [15563845.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):744-50 [15720800.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):915-23 [15767370.001]
  • [Cites] J Mol Med (Berl). 2005 Apr;83(4):258-66 [15662540.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1763-75 [16314486.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3796-803 [16517750.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):867-75 [16461741.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):900-5 [16690127.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11194-206 [17145864.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):3-14 [17311529.001]
  • [Cites] BMC Genomics. 2007;8:140 [17540040.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):225-33 [18176604.001]
  • [Cites] Cell Signal. 2008 Feb;20(2):269-76 [17890055.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Mol Cell Biol. 2008 May;28(10):3538-47 [18347055.001]
  • [Cites] FASEB J. 2008 Jul;22(7):2285-96 [18276832.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):861-7 [11309334.001]
  • (PMID = 20028769.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-119004; United States / NCI NIH HHS / CA / P01 CA091844-020002; United States / NCI NIH HHS / CA / P01 CA091844; United States / NCI NIH HHS / CA / CA091844-020002; United States / NCI NIH HHS / CA / P01 CA091844-010002; United States / NCI NIH HHS / CA / P50 CA070907-119004; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / 1P01 CA91844-03; United States / NCI NIH HHS / CA / CA091844-010002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-1; 0 / NF-kappa B; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases
  • [Other-IDs] NLM/ NIHMS155236; NLM/ PMC2811365
  •  go-up   go-down


29. Liu Y, Yu L, Lin J: [Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):273-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion].
  • BACKGROUND: Malignant pleural effusion is usually caused by lung cancer, and tumor markers may be helpful to its differential diagnosis.
  • The aim of this study is to explore the clinical value of serum and pleural effusion pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), cyto- keratin fragment 19 (CYFRA21-1) and carcinoembryonic antigen (CEA) in differential diagnosis and histological typing of malignant pleural effusion caused by lung cancer.
  • METHODS: According to histological type of primary tumor, 99 patients with malignant pleural effusion caused by lung cancer were divided into small cell lung cancer (SCLC) group, adenocarcinoma group and squamous cell carcinoma group, with 37 patients with benign pleural effusion and 35 healthy persons as controls.
  • In the adenocarcinoma group and squamous cell carcinoma group, combined detection of pleural effusion CEA+CYFRA21-1 (on parallel test) showed the highest Youden index and accuracy.
  • CONCLUSIONS: Detection of pleural effusion tumor markers ProGRP, CYFRA21-1, NSE and CEA is of great clinical value in differential diagnosis and histological typing of malignant pleural effusion.
  • Pleural effusion CEA+CYFRA21-1 (on parallel test) is a good auxiliary diagnosis index for malignant pleural effusion caused by adenocarcinoma and squamous cell carcinoma of the lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172161.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Calabrese L, Jereczek-Fossa BA, Jassem J, Rocca A, Bruschini R, Orecchia R, Chiesa F: Diagnosis and management of neck metastases from an unknown primary. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):2-12
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of neck metastases from an unknown primary.
  • Neck lymph node metastases from occult primary constitute about 5%-10% of all patients with carcinoma of unknown primary site.
  • The most frequent histological finding is Squamous Cell Carcinoma, particularly when the upper neck is involved.
  • Thoracic, and abdominal primaries (especially from lung, oesophagus, stomach, ovary or pancreas) should be sought in the case of adenocarcinoma and involvement of the lower neck.
  • In early stages (N1), neck dissection and radiotherapy seem to have similar efficacy, whereas more advanced cases (N2, N3) require combined approaches.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):411-6 [12634970.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Sep;260(8):436-43 [12684829.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Oct;260(9):490-3 [12739031.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):153-64 [15023433.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Cancer Treat Rev. 2004 Jun;30(4):369-84 [15145511.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] Radiology. 1974 Mar;110(3):659-63 [4130047.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):517-22 [911038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):73-6 [422418.001]
  • [Cites] Clin Radiol. 1980 May;31(3):355-8 [7428277.001]
  • [Cites] Radiology. 1984 Sep;152(3):749-53 [6463256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 May;12(5):733-40 [3710857.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Jun;94(5):605-10 [3088524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2101-10 [3793546.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):331-3 [11241001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):55-63 [11316546.001]
  • [Cites] Acta Oncol. 2001;40(1):24-8 [11321655.001]
  • [Cites] Radiother Oncol. 2001 Jun;59(3):319-21 [11369074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):535-40 [11398889.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):214-6 [11408815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):4-9 [11516844.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1057-8 [11583184.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1605-9 [11822762.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):510-5 [2736495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):289-94 [2303361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):919-28 [2211260.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):443-6 [2221252.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1388-93 [2248737.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):463-9 [2258284.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):177-83 [2037468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):884-90 [1495353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):619-22 [8454479.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1756-61 [8348505.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):58-63 [8125789.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):119-47 [8156538.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):395-9 [7977958.001]
  • [Cites] Laryngoscope. 1995 May;105(5 Pt 1):548-50 [7760677.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):190-8 [7782203.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):222-8 [7546677.001]
  • [Cites] Radiother Oncol. 1995 Jun;35(3):206-11 [7480823.001]
  • [Cites] Radiology. 1996 Jun;199(3):761-6 [8638002.001]
  • [Cites] J Laryngol Otol. 1996 Apr;110(4):353-6 [8733457.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1996;113(4):212-8 [9033687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):797-802 [9128954.001]
  • [Cites] Strahlenther Onkol. 1997 Jul;173(7):362-8 [9265258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):291-6 [9308930.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(5):322-9 [9368728.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):121-5 [9537194.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1998 Apr;23(2):158-63 [9597287.001]
  • [Cites] Laryngoscope. 1998 Oct;108(10):1578-83 [9778305.001]
  • [Cites] Head Neck. 1998 Dec;20(8):674-81 [9790287.001]
  • [Cites] Head Neck. 1998 Dec;20(8):739-44 [9790297.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1605-10 [9818813.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):33-40 [9886695.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):599-604 [10203278.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):114-8 [10391570.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jul;108(7 Pt 1):700-4 [10435932.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):214-8 [10439166.001]
  • [Cites] Oncologist. 2005 Mar;10(3):215-24 [15793225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jan;122(1):52-5 [10629482.001]
  • [Cites] Int J Hyperthermia. 2000 Jan-Feb;16(1):85-93 [10669319.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):263-8 [10779057.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 2000 May;103(5):524-8 [10853340.001]
  • [Cites] Head Neck. 2000 Jul;22(4):336-40 [10862015.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Jul 8;144(28):1355-60 [10923158.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301 [10964310.001]
  • [Cites] Otolaryngol Pol. 2000;54 Suppl 31:258-61 [10974901.001]
  • [Cites] Head Neck. 2002 Mar;24(3):236-46 [11891955.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2002;56(1):77-82 [11894635.001]
  • [Cites] Head Neck. 2002 Apr;24(4):361-9 [11933178.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):323-9 [11981279.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1024-30 [12173016.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):569-74 [12206272.001]
  • [Cites] Cancer Control. 2002 Sep-Oct;9(5):387-99 [12410178.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):2009-14 [12439171.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Dec;40(6):484-7 [12464205.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Head Neck. 2003 Feb;25(2):138-45 [12509797.001]
  • [Cites] Acta Otorrinolaringol Esp. 2002 Oct;53(8):601-6 [12530200.001]
  • (PMID = 16080309.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 102
  • [Other-IDs] NLM/ PMC2639847
  •  go-up   go-down


31. Iranzo V, Bremnes RM, Almendros P, Gavilá J, Blasco A, Sirera R, Camps C: Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer. Lung Cancer; 2009 Jan;63(1):63-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.
  • Combined modality treatment with chemotherapy (CT) and radiotherapy (RT) in stage III non-small-cell lung cancer is considered as standard therapy.
  • 31 patients with non-operable stage IIIA or IIIB NSCLC without pleural effusion were included in this study: 30 males, 1 female; median age 66 years (range: 50-81); 32% with non-operable stage IIIA and 68% with stage IIIB without pleural effusion; 61% squamous cell carcinoma, 32% adenocarcinoma and 7% other histologies.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550204.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY, Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY: A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer; 2010 Oct;70(1):71-6
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer.
  • BACKGROUND: Although platinum-based doublet chemotherapy is considered as standard of care for patients with advanced non-small cell lung cancer (NSCLC), most of them are eventually supposed to experience disease progression.
  • Among the responders, four patients had adenocarcinoma and two had squamous cell carcinoma.
  • Four patients (12.5%) experienced grade 3 non-hematologic toxicities; four asthenia (12.5%), two anorexia (6.3%), and one stomatitis (3.1%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20096475.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


33. Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T: Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg; 2009 Sep;36(3):433-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
  • OBJECTIVE: Analysis of single centre results and identification of prognostic factors of surgical combined modality treatment in pathological proven stage IIIA-N2 non-small cell lung cancer (NSCLC).
  • Adenocarcinoma and squamous cell carcinomas were equally present (48% vs 43%).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2009 Sep;36(3):431-2 [19524447.001]
  • (PMID = 19502079.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS: Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1037-44
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
  • PURPOSE: For locoregionally advanced inoperable non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy has become a standard therapy.
  • The median age was 59 years and 13 patients had IIIA and 27 had IIIB; 24 had squamous ca, 12 had adenocarcinoma, and 4 had others.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024178.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


35. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • Recent advances in the treatment of pulmonary adenocarcinoma have increased the need for accurate typing of non-small cell carcinomas.
  • Immunohistochemistry for thyroid transcription factor-1 is widely used in the diagnosis of pulmonary adenocarcinomas because it marks approximately 75% of lung adenocarcinomas and is negative in most squamous cell carcinomas and adenocarcinomas of other organs.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • All squamous cell carcinomas, adenocarcinomas of the colon, pancreas and breast, and mesotheliomas were negative for both markers.
  • Of the renal tumors, napsin A was positive in most of papillary renal cell carcinomas (79%), about one third (34%) of clear cell renal cell carcinomas, and in a single case of chromophobe renal cell carcinoma (3%).
  • In the thyroid, only 2 cases of papillary thyroid carcinoma (5%), both with tall cell morphology, were positive for napsin A, whereas all other papillary and follicular carcinomas were negative.
  • As expected, all renal tumors were thyroid transcription factor-1 negative, and all thyroid tumors, except for one papillary carcinoma, were thyroid transcription factor-1 positive.
  • Napsin A is a sensitive marker for pulmonary adenocarcinoma and is also expressed in a subset of renal cell carcinomas, particularly of the papillary type, as well as in rare cases of papillary thyroid carcinomas.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


36. Lee PN, Hamling J: The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews. BMC Cancer; 2009;9:256
MedlinePlus Health Information. consumer health - Smokeless Tobacco.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews.
  • Boffetta et al. and ourselves recently reviewed the evidence on cancer, based on Scandinavian and US studies.
  • Boffetta et al. claimed a significant 60-80% increase for oropharyngeal, oesophageal and pancreatic cancer, and a non-significant 20% increase for lung cancer, data for other cancers being "too sparse".
  • We found increases less than 15% for oesophageal, pancreatic and lung cancer, and a significant 36% increase for oropharyngeal cancer, which disappeared in recent studies.
  • We found no association with stomach, bladder and all cancers combined, using data as extensive as that for oesophageal, pancreatic and lung cancer.
  • RESULTS: One major reason for the difference is our more consistent approach in choosing between study-specific never smoker and combined smoker/non-smoker estimates.
  • For pancreatic cancer, their review included significantly increased never smoker estimates in one study and combined smoker/non-smoker estimates in another, omitting a combined estimate in the first study and a never smoker estimate in the second showing no increase.
  • For oesophageal cancer, never smoker results from one study showing a marked increase for squamous cell carcinoma were included, but corresponding results for adenocarcinoma and combined smoker/non-smoker results for both cell types showing no increase were excluded.
  • For oropharyngeal cancer, Boffetta et al. included a markedly elevated estimate that was not smoking-adjusted, and overlooked the lack of association in recent studies.
  • A systematic meta-analysis using pre-defined procedures and all relevant data gives a lower estimate of cancer risk from smokeless tobacco (probably 1-2% of that from smoking) than does the previous review by Boffetta et al.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] BMC Med. 2009;7:36 [19638245.001]
  • [Cites] J Natl Cancer Inst. 1969 Jun;42(6):1069-94 [5793187.001]
  • [Cites] Am J Epidemiol. 1970 May;91(5):486-99 [5438996.001]
  • [Cites] J Natl Cancer Inst. 1977 Mar;58(3):525-47 [557114.001]
  • [Cites] N Engl J Med. 1981 Mar 26;304(13):745-9 [7193288.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Head Neck Surg. 1986 Nov-Dec;9(2):104-10 [3623935.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3282-7 [3365707.001]
  • [Cites] J Natl Cancer Inst. 1988 Dec 21;80(20):1620-5 [3193480.001]
  • [Cites] J Clin Epidemiol. 1991;44(2):127-39 [1995774.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Oct;49(10):1044-7; discussion 1048-9 [1653824.001]
  • [Cites] J Clin Epidemiol. 1992 Mar;45(3):223-31 [1569419.001]
  • [Cites] Am J Epidemiol. 1992 Jun 1;135(11):1301-9 [1626547.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1369-75 [8339227.001]
  • [Cites] Cancer Causes Control. 1993 Sep;4(5):477-82 [8218880.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1137-44 [7721514.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):15-9 [8993792.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1367-75 [9529030.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):341-6 [9663593.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] Br Med J. 1957 May 18;1(5028):1137-43 [13426561.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):992-5 [15645430.001]
  • [Cites] Cancer Causes Control. 2005 May;16(4):347-58 [15953977.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1107-15 [16184477.001]
  • [Cites] Acta Otolaryngol. 2005 Sep;125(9):991-8 [16193590.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2547-56 [17492688.001]
  • [Cites] Lancet. 2007 Jun 16;369(9578):2015-20 [17498797.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1095-9 [17973262.001]
  • [Cites] BMC Public Health. 2007;7:334 [18005437.001]
  • [Cites] Stat Med. 2008 Mar 30;27(7):954-70 [17676579.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):168-73 [18412245.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):667-75 [18598931.001]
  • [Cites] BMC Cancer. 2008;8:356 [19046421.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):55-8 [14744733.001]
  • (PMID = 19638246.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3087330
  •  go-up   go-down


37. Cicenas S, Zaliene A, Atkocius V: [Treatment outcome of locally advanced stage IIIA/B lung cancer]. Medicina (Kaunas); 2009;45(6):452-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcome of locally advanced stage IIIA/B lung cancer].
  • OBJECTIVE: To determine survival of patients with stage IIIA/B non-small cell lung cancer considering disease stage and treatment methods.
  • MATERIAL AND METHODS: A total of 304 patients with non-small cell lung cancer were treated at the Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University, in 2000-2004.
  • Stage IIIA (T3N1-2M0) cancer was diagnosed for 193 (63.5%) patients and stage IIIB (T4N0-1M0) cancer was diagnosed for 111 (36.5%) patients.
  • According to morphology, there were 219 (72%) patients with squamous cell lung cancer, 80 (26.3%) with adenocarcinoma, and 5 (1.7%) patients with large cell carcinoma.
  • Surgery was performed in 145 patients: 84 (57.9%) patients underwent lung resection (T3-4N0-1M0), 51 (35.2%) patients - thoracotomy, and 10 (6.7%) patients - other palliative thoracic procedures (mediastinotomy, pleurectomy, mediastinoscopy).
  • The median and mean survival of patients with stage IIIA cancer was 8.3 months and 10.4 months, respectively, and that of patients with stage IIIB cancer - 6.4 months and 9.0 months, respectively (P < or =0.05).
  • The median survival of the patients with stage IIIA cancer who received a combination of operation, chemotherapy, and radiation therapy with a total dose of >40 Gy was 14.4 months (mean, 14.7 months), and the median survival of those who received operation, chemotherapy, and radiation therapy with a total dose of < or =40 Gy was 9.7 months (mean, 14.1 months); the median survival of the patients who underwent surgery alone was 4.9 months (mean, 6.7 months) (P=0.004 and P=0.007), respectively.
  • There was a significant difference in the median survival comparing the patients with stage IIIB cancer who underwent surgery alone and those who received a combination of radiation therapy and chemotherapy (median survival of 5.0 months [mean, 8.1 months] versus 16.8 months [mean, 17.6 months], respectively; P < or =0.05).
  • CONCLUSIONS: Disease stage had an influence on the survival of patients with non-small cell lung cancer: patients with stage IIIA (T3N0-1M0) cancer without metastases to mediastinal lymph nodes (N factor) survived longer than patients with stage IIIB (T4N1-2M0) cancer, where not only N factor had an impact but T factor as well.
  • Better treatment outcomes, i.e. longer survival, can be achieved when a combination of three treatment types - surgery, chemotherapy, and radiation therapy - is applied to patients with stage IIIA or IIIB non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Lung / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Radiotherapy Dosage. Thoracotomy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605965.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Li B, Li Z, Zhang Y, Li Y, Wu W: [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):469-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung].
  • BACKGROUND: Adenosquamous carcinoma of the lung is a rare pathologic type of lung cancer.
  • The aim of this study is to explore the clinical features of adenosquamous carcinoma of the lung.
  • METHODS: A total of 115 patients with adenosquamous carcinoma of the lung were retrospectively analysed, who were diagnosed by operation and pathology.
  • There were 14 patients (12.17%) without any symptom and 16 patients had residual carcinoma at the resection margin (14.04%).
  • CONCLUSIONS: The incidence of adenosquamous carcinoma of the lung in young women (under 49 years, especially under 39 years) is rather high.
  • The residual carcinoma at the resection margin often occurs after routine operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176475.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


39. Yu JQ, Yang ZG, Austin JH, Guo YK, Zhang SF: Adenosquamous carcinoma of the lung: CT-pathological correlation. Clin Radiol; 2005 Mar;60(3):364-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the lung: CT-pathological correlation.
  • AIM: To correlate CT morphological features and histopathological findings of adenosquamous carcinoma of the lung.
  • MATERIALS AND METHODS: In all, 29 patients underwent contrast-enhanced CT of an adenosquamous carcinoma of the lung, followed by resection of the cancer.
  • These CT features corresponded mainly to solid tumour growth, which was composed of both squamous cell carcinomatous and adenocarcinomatous tissue.
  • CONCLUSION: Adenosquamous carcinoma of the lung is shown to be characteristically a solid, lobulated nodule or mass, more commonly peripheral than central.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710140.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Damadoğlu E, Aybatli A, Yalçinsoy M, Tahaoğlu C, Atasalihi A, Akkaya E, Yilmaz A: [Adenosquamous carcinoma of the lung (an analysis of 13 cases)]. Tuberk Toraks; 2005;53(2):161-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous carcinoma of the lung (an analysis of 13 cases)].
  • Adenosquamous carcinoma of the lung is a rare disease.
  • In this study, we retrospectively evaluated 13 patients with adenosquamous carcinoma of the lung diagnosed at our center between January 2001 and May 2004.
  • Preoperative pathological diagnosis was squamous cell carcinoma in eight patients, non-small cell lung carcinoma in four patients and adenocarcinoma in one patient.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Lung Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100653.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


41. Li J, Zhang DC, He J, Liu XY, Mu JW, Zhang LZ: [The rule of lymph node metastasis of adenosquamous carcinoma of the lung]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):524-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The rule of lymph node metastasis of adenosquamous carcinoma of the lung].
  • OBJECTIVE: To investigate the rule of lymph node metastasis of adenosquamous carcinoma of the lung.
  • METHODS: The data of 361 surgically treated patients with adenosquamous carcinoma of the lung from October 1965 to June 2003 were collected and retrospectively reviewed.
  • The skip mediastinal lymph node metastasis but N1 negative most commonly metastasized to station 7, then to station 4 from the tumor in the right lung and 5 from the tumor in the left lung.
  • CONCLUSION: The lung cancer growing in a different location has a different route and skipping metastasis to mediastinal lymph nodes.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950701.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK, Chang J: Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer; 2007 Feb 1;109(3):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
  • BACKGROUND: Adenosquamous carcinoma of the lung is composed of adenocarcinomatous and squamous cell carcinomatous components.
  • The epidermal growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and rarely in squamous cell carcinoma of lung.
  • Attempts to investigate the EGFR mutation status in each component of adenosquamous carcinoma and to characterize the patients according to mutation status may help to understand the histogenesis of adenosquamous carcinoma.
  • METHODS: The mutation status of EGFR kinase domain from exon 18 to 21 was investigated in 25 Korean patients with adenosquamous carcinoma by polymerase chain reaction-single strand conformation polymorphism using the tissues of each component from the adenosquamous carcinoma tumor.
  • Identical EGFR mutations in both components of adenosquamous carcinoma were confirmed by nucleotide sequencing.
  • CONCLUSIONS: The frequency of EGFR mutation and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas.
  • Identical EGFR mutations in both components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17186532.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


43. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M, Fujii Y: Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer; 2007 Jan;55(1):129-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung.
  • We have investigated 26 adenosquamous lung cancer tissues and found that four EGFR mutations were mainly in female and non-smoker lung cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lung Cancer. 2006 Apr;52(1):47-52 [16503085.001]
  • (PMID = 17156891.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


44. Diaz A, Batista AE, Montero E: Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. J Interferon Cytokine Res; 2009 Aug;29(8):433-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.
  • Interferon-alpha (IFN-alpha) induces growth inhibition but also may up-regulate the EGFR expression in some cancer cell lines.
  • We aimed to determine whether the IFN-alpha combined with an EGFR-specific monoclonal antibody (nimotuzumab) may affect the growth of human tumor epithelial cell lines with different EGFR expression levels.
  • H125, a lung adenosquamous carcinoma, and A431, a vulvar epidermoid carcinoma, cell lines express intermediate and high levels of EGFR, respectively, whereas MDA MB231, a breast adenocarcinoma cell line expresses undetectable levels of EGFR measured by flow cytometry/FACS.
  • We found that IFN-alpha alone inhibited in a dose-dependent fashion the growth of all cell lines, but only up-regulated the EGFR expression in the lung carcinoma-derived cell line.
  • Noteworthy, the combined treatment did not modify the complement-mediated cytotoxicity of the antibody although the antiproliferative activity of nimotuzumab in H125 cells in vitro increased when an IFN-alpha-conditioning treatment was used.
  • In conclusion, this study may provide insights about the rational use of EGFR inhibitors into the immunopharmacological management of targeted therapies including the IFN-alpha for lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Epithelial Cells / immunology. Growth Inhibitors / metabolism. Immunologic Factors / pharmacology. Immunotherapy. Interferon-alpha / metabolism. Lung Neoplasms / immunology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Cell Growth Processes / drug effects. Cell Line, Tumor. Cell Separation. Complement System Proteins / metabolism. Cytotoxicity, Immunologic / drug effects. Dose-Response Relationship, Immunologic. Drug Synergism. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Vulvar Neoplasms / immunology. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / pathology. Vulvar Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514842.001).
  • [ISSN] 1557-7465
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Growth Inhibitors; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / nimotuzumab; 9007-36-7 / Complement System Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


45. Sousa M, Cavadas S, Moreira MJ, Mellidez JC: Erlotinib in non-small cell lung cancer's second line treatment. Clinical case. Rev Port Pneumol; 2008 Oct;14 Suppl 3:S79-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib in non-small cell lung cancer's second line treatment. Clinical case.
  • [Transliterated title] Erlotinib no tratamento de segunda linha do cancro do pulmão de não pequenas células. Caso clínico.
  • Male, of 58 years, caucasian, construction worker, non smoker, with depressive syndrome, biliary lithiasis, renal cysts, surgery for benign intestinal polyps and relevant familiar history - aunt with lung cancer and mother with colon cancer.
  • He initiated thorax pain and vomitting and made a chest x-ray, showing a right basal lung mass.
  • During the etiologic study, he was submitted to thoracotomy with biopsy, in April 2006 - "fine granulations, spread for all the pulmonary field", allowing the diagnosis - adenosquamous lung carcinoma, stage IV (16/05/2006).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967692.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Lung cancer / Neoplasia do pulmão / adenosquamous carcinoma / carboplatin / carboplatino / carcinoma adenoescamoso / erlotinib / vinorelbina / vinorelbine
  •  go-up   go-down


46. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


47. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • METHOD: This study reviewed the patient charts of 11 (1.6%) ADSQ cases among 779 patients with primary lung cancer who underwent a lung resection.
  • Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and 1 bladder cancer.
  • ADSQ was found less frequently in males than squamous cell carcinoma (SQ).
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • ADSQ had a significantly correlation with double cancer (ADSQ vs. non- ADSQ p = 0.03).
  • A multivariate analysis showed no significant prognostic difference between the patients with ADSQ and non- ADSQ.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • However, surgeons must be cautious of any coexistent double cancer because approximately half of all patients with ADSQ of the lung have double cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


48. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Herpes Zoster / complications. Respiratory Paralysis / etiology
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


49. Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P, Baloch Z: Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol; 2009 Mar;37(3):178-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.
  • The current FDA-approved standard of care for nonsmall cell lung cancer is Carboplastin/Taxol/Avastin based upon an impressive survival benefit; however, patients with squamous carcinoma (SQCC) cannot receive Avastin because of a 30% mortality rate due to fatal hemoptysis.
  • In this study we evaluated the role of cytomorphology and immunohistochemistry in differentiating SQCC from adenocarcinoma (ADC) in lung FNA specimens.
  • The case cohort included 53 FNA cases of nonsmall cell lung carcinoma with surgical pathology follow-up.
  • The cell block material was available in 23 cases (11 ADC and 12 SQCC) to perform immunohistochemical stains for TTF-1, CK7, CK20, P63, and CK5/6.
  • The number of cases classified correctly on the basis of cytomorphology was 66% for ADC and 53% for SQCC (combined accuracy 60%).
  • Cytomorphology alone may not be able to stratify all cases of nonsmall cell lung carcinoma into ADC and SQCC in FNA specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / diagnosis. Keratin-5 / analysis. Keratin-6 / analysis. Lung Neoplasms / diagnosis. Membrane Proteins / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Fine-Needle. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Keratins / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19170169.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / DNA-Binding Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins; 0 / TTF1 protein, human; 68238-35-7 / Keratins
  •  go-up   go-down


50. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, Beer DG: Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res; 2006 Aug 1;66(15):7466-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
  • Non-small-cell lung cancers (NSCLC) compose 80% of all lung carcinomas with squamous cell carcinomas (SCC) and adenocarcinoma representing the majority of these tumors.
  • We have profiled primary squamous cell lung carcinomas from 129 patients using Affymetrix U133A gene chips.
  • Finally, we combined the SCC classifier with our previously identified adenocarcinoma prognostic signature and showed that the combined classifier had a predictive accuracy of 71% in 72 NSCLC samples also showing significant differences in overall survival (log-rank P = 0.0002; HR, 3.54; 95% CI, 1.74-7.19).
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885343.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE4573
  • [Grant] United States / NCI NIH HHS / CA / CA 46592
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Okwuosa TM, Williams KA: "Mass-ive" infarction: case report and review of myocardial metastatic malignancies. J Nucl Cardiol; 2008 Sep-Oct;15(5):719-26
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac metastases from lung cancer are rarely diagnosed ante mortem and usually cause no symptoms or signs.
  • In this case report cardiac metastasis from a primary adenosquamous cancer of the lung presented as myocardial infarction in a 61-year-old man.
  • His diagnosis was made and confirmed via multimodality imaging of the heart, which is also reviewed in depth.
  • [MeSH-major] Heart Neoplasms / secondary. Lung Neoplasms / pathology. Myocardial Infarction / pathology. Myocardium / pathology. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761275.001).
  • [ISSN] 1532-6551
  • [Journal-full-title] Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  • [ISO-abbreviation] J Nucl Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


52. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C: Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg; 2006 Jun;81(6):1988-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping.
  • BACKGROUND: Adenocarcinoma (AC) is the most common lung cancer, followed by squamous cell carcinoma (SCC).
  • Controversy exists concerning both cell types.
  • One hundred fifty-nine patients with ACs demonstrated a pure histologic pattern according to the 1999 World Health Organization classification, and 406 were of the mixed subtype including cell types with potentially different aggressiveness.
  • Therefore, we compared subgroups according to presence or not of bronchioloalveolar carcinoma or solid adenocarcinoma with mucin component, or both.
  • Further studies of this cell type, which should be looked for carefully, may help improve targetting adjuvant therapies.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / statistics & numerical data. Combined Modality Therapy. Female. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / methods. Pneumonectomy / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant / statistics & numerical data. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731118.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P: Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer; 2007 Jan;55(1):25-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
  • Alterations in cell cycle regulation and apoptosis leading to malignant transformation could be caused by common genetic variants in tumor suppressor genes.
  • The effects of the TP53 polymorphism Arg72Pro on lung cancer risk have been investigated in numerous studies with, however, conflicting results.
  • We therefore investigated the combined effects of polymorphisms in TP53 (Arg72Pro) and p21/CDKN1A (Ser31Arg) and smoking on lung cancer risk.
  • Our case-control study consisted of 405 patients with lung cancer, mainly squamous-cell carcinoma (185) and adenocarcinoma (177) and 404 unmatched tumor-free hospital controls.
  • Multivariate regression analysis showed a moderate but statistically significant risk of lung cancer overall and especially of squamous-cell carcinoma (OR, 1.65; CI, 1.10-2.47) for TP53 72Pro allele carriers.
  • The risk was markedly increased in heavy smokers (>20 pack-years) with squamous-cell carcinoma (OR, 2.80 in patients homozygous for 72Pro; CI, 1.19-6.58), but not in light smokers (<or=20 pack-years).
  • The results for the p21 Ser31Arg polymorphism suggested that 31Ser is a moderate-risk allele for squamous-cell carcinoma.
  • Analysis of the combined effects of the two polymorphisms revealed a higher OR for TP53 72Pro carriers homozygous for p21 31Ser than for 72Pro carriers in general; this effect being most pronounced in heavy smokers with squamous-cell carcinoma (OR, 3.84; CI, 1.46-10.1).
  • Our data indicate that the TP53 Arg72Pro polymorphism increases the risk for squamous-cell carcinoma mainly in heavy smokers.
  • The observed interaction with smoking is biologically plausible as, for the 72Pro p53 variant, decreased apoptosis and extended G1 cell cycle arrest is reported after carcinogen exposure.
  • [MeSH-major] Amino Acid Substitution. Carcinoma, Squamous Cell / genetics. Codon / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Genetic Variation. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide. Smoking / adverse effects. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Arginine. Female. Humans. Male. Middle Aged. Odds Ratio. Proline. Risk Factors. Serine

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059853.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Codon; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; 452VLY9402 / Serine; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


54. Zhao LQ, Hou SC, Li H, Hu B, Wang Y: [Combined therapy for stage IIIa non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi; 2005 Aug 3;85(29):2030-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined therapy for stage IIIa non-small cell lung cancer].
  • OBJECTIVE: To evaluate the long-term outcome of combined therapy for stage IIIa non-small cell lung cancer (NSCLC).
  • The patients were classified according to the TNM staging, and the specimens of resected cancer were examined pathologically.
  • The 5-year survival rate of the combined therapy group was 23.5%, significantly higher than that of the surgical resection alone group (P < 0.01).
  • The 5-year survival rate was 27.6% for the squamous cell carcinoma (SCC), and 23.5% for adenocarcinoma (AC) in the combined therapy group; and was 115.2% for SCC and 9.9% for AC in the surgical resection alone group (all P < 0.01).
  • CONCLUSION: The curative effectiveness of combined therapy is significantly better than surgical resection alone for stage IIIa NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant


55. van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A: Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg; 2008;8:21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
  • BACKGROUND: A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases (cT1-3 N0-1 M0).
  • We previously reported that after neoadjuvant chemoradiotherapy with weekly administrations of Carboplatin and Paclitaxel combined with concurrent radiotherapy nearly always a complete R0-resection could be performed.
  • The study compares neoadjuvant chemoradiotherapy followed by surgery with surgery alone in patients with potentially curable esophageal cancer, with inclusion of 175 patients per arm.The objectives of the CROSS trial are to compare median survival rates and quality of life (before, during and after treatment), pathological responses, progression free survival, the number of R0 resections, treatment toxicity and costs between patients treated with neoadjuvant chemoradiotherapy followed by surgery with surgery alone for surgically resectable esophageal adenocarcinoma or squamous cell carcinoma.
  • DISCUSSION: This study will contribute to the evidence on any benefits of neoadjuvant treatment in esophageal cancer patients using a promising chemoradiotherapy regimen.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / therapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / surgery. Esophageal Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):391-3 [7959579.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):442-7 [11208837.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(4):470-7 [11267856.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(1):CD001556 [11279723.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2165-74 [11391598.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(2):223-30 [11803139.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):274-9 [11943125.001]
  • [Cites] Cancer. 2002 May 1;94(9):2511-6 [12015777.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):348-56 [12243807.001]
  • [Cites] Lung Cancer. 2002 Oct;38(1):85-9 [12367798.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):754-61 [12900366.001]
  • [Cites] Ned Tijdschr Geneeskd. 2003 Oct 25;147(43):2097-100 [14619197.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):947-54 [15151953.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Control Clin Trials. 1981 Jun;2(2):93-113 [7273794.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Aug;96(2):242-8 [2456424.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] J Surg Oncol. 1994 Jul;56(3):191-7 [7518020.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1446-50 [1365692.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):980-4 [8826870.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3156-74 [8955662.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1091-8 [8985031.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Aug;114(2):210-7 [9270638.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-89-S12-95 [9331129.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):155-61 [9422572.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3316-22 [9779707.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Surgery. 2005 Feb;137(2):172-7 [15674197.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1389-94 [16670722.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] BMC Med. 2004 Sep 24;2:35 [15447788.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):931-7 [10863062.001]
  • (PMID = 19036143.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN80832026
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2605735
  •  go-up   go-down


56. Stanford JL, Stanford CA, O'Brien ME, Grange JM: Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer; 2008 Jan;44(2):224-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung.
  • Immunotherapy with a heat-killed suspension of Mycobacterium vaccae (SRL172), given with chemotherapy, in a phase III trial against non-small-cell-lung cancer showed no improvement in the primary endpoint of survival over chemotherapy alone in the initial published analysis.
  • Secondary analyses based on compliance with therapy showed that immunotherapy led to significantly improved survival times of patients with adenocarcinoma but, by contrast, had no beneficial effect on survival times of patients with squamous cell carcinoma.
  • Survival of adenocarcinoma patients receiving SRL172 was increased by a mean of 135 days (p=0.0009, Kaplan-Meier log rank test) and survival after 4 or 5 doses of SRL172 showed a difference of greater than 100 days (p<0.05, Mantel-Hänszel log rank test) in the group receiving SRL172 in addition to chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bacterial Vaccines / therapeutic use. Immunotherapy / methods. Lung Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Patient Compliance. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928219.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Vaccines; 0 / SRL172
  •  go-up   go-down


57. Tse LA, Yu IT, Au JS, Yu KS, Kwok KP, Qiu H, Wong TW: Environmental tobacco smoke and lung cancer among Chinese nonsmoking males: might adenocarcinoma be the culprit? Am J Epidemiol; 2009 Mar 1;169(5):533-41
MedlinePlus Health Information. consumer health - Secondhand Smoke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Environmental tobacco smoke and lung cancer among Chinese nonsmoking males: might adenocarcinoma be the culprit?
  • No studies have specifically reported the association of lung adenocarcinoma with environmental tobacco smoke (ETS) exposure among nonsmoking males.
  • The objective of this study was to examine the exposure-response relation between ETS exposure and lung cancer among nonsmoking males.
  • In particular, the association with adenocarcinoma of the lung was studied.
  • A total of 132 Chinese male nonsmokers with newly diagnosed primary lung cancer and 536 nonsmoking community referents were interviewed about ETS exposures from the household and/or workplace, including ever ETS exposure, sources of exposure, number of smoking cohabitants/coworkers, and smoker-years.
  • Univariate logistic regression analyses showed a weak association between all lung cancers and ever ETS exposure from the household and/or workplace (odds ratio (OR) = 1.11, 95% confidence interval (CI): 0.74, 1.67), but an increased risk was restricted to adenocarcinoma (OR = 1.68, 95% CI: 1.00, 2.38).
  • After adjustment for family cancer history and other confounders, excess risk (OR = 1.62, 95% CI: 0.91, 2.88) still persisted for adenocarcinoma, although it was no longer statistically significant.
  • Exposure-response relations for adenocarcinoma were found with increasing levels of all ETS indices when exposures from the household and workplaces were combined.
  • The consistent exposure-response relations between ETS exposures and adenocarcinoma suggested a probable causal link, which would have to be confirmed by future larger studies.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Lung Neoplasms / epidemiology. Lung Neoplasms / etiology. Tobacco Smoke Pollution / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Case-Control Studies. Hong Kong / epidemiology. Humans. Interviews as Topic. Logistic Models. Male. Middle Aged. Occupational Exposure / adverse effects. Risk Factors. Smoking Cessation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126588.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  •  go-up   go-down


58. Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L, Rusch VW: Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol; 2007 Dec;2(12):1117-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus.
  • INTRODUCTION: In a previous study of prognostic factors in patients with loco-regionally advanced adenocarcinoma of the esophagus treated with chemo-radiotherapy (CRT) followed by resection, we found that residual nodal disease was most prognostic of outcome.
  • In this study, we evaluated prognostic factors among patients with squamous cell carcinoma (SCC) of the esophagus who have undergone a similar treatment regimen.
  • CONCLUSIONS: Unlike adenocarcinoma, in which residual nodal disease after CRT is the most significant predictor of survival, in SCC of the esophagus, pt-pCR or minimal residual local disease after CRT predicts the best survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / mortality. Esophageal Neoplasms / therapy. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Probability. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


59. Prokakis C, Koletsis E, Apostolakis E, Panagopoulos N, Charoulis N, Velissaris D, Filos K, Dougenis D: Combined heart surgery and lung tumor resection. Med Sci Monit; 2008 Mar;14(3):CS17-21
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined heart surgery and lung tumor resection.
  • BACKGROUND: Combined heart surgery and lung resection remains a controversial issue.
  • CASE REPORTS: A retrospective study is presented of five male patients who underwent combined surgical treatment for heart and lung disease in a one-step procedure between November 2004 and November 2006.
  • The other two patients underwent pulmonary wedge resection, one combined with coronary bypass and the other with ascending aorta replacement.
  • CONCLUSIONS: Combined heart surgery and lung resection can be performed without increased mortality and/or morbidity.
  • [MeSH-major] Adenocarcinoma / surgery. Aortic Valve Stenosis / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Heart tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301362.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


60. Kawaguchi K, Mori S, Usami N, Fukui T, Mitsudomi T, Yokoi K: Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. Lung Cancer; 2009 Apr;64(1):41-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients.
  • The optimal extent of a combined resection in patients with lung cancer invading the chest wall remains controversial.
  • To assess whether specific preoperative findings could lead to the precise evaluation of the depth of chest wall invasion and evade en-bloc resection of the chest wall in cases of tumor invasion limited to the parietal pleura, 132 patients with resected lung cancer involving the chest wall were retrospectively surveyed for the preoperative findings, surgical procedures, pathological results, and survival.
  • In patients with lung cancer involving the chest wall, chest pain and/or invading on chest CT suggested that an en-bloc resection was a suitable surgical procedure, because 79% of those patients had deep invasion.
  • Therefore, the CT findings of obvious tumor invasion beyond the parietal pleura and/or the presence of chest pain indicate the need to perform an en-bloc resection in patients with lung cancer involving the chest wall.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Pneumonectomy / methods. Thoracic Surgical Procedures / methods. Thoracic Wall / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926593.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


61. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M: Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol; 2009 May;22(5):709-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung.
  • Lung cancer classification in small-cell and non-small-cell types was recently challenged by data on the differential efficacy of new cytotoxic agents in specific histotypes.
  • An accurate histotype definition has therefore gained interest in both preoperative and surgical materials, but is a hard task especially in undifferentiated large-cell tumors lacking morphological signs of squamous or glandular differentiation.
  • The responsiveness of these latter subtypes to new drugs apparently more selective for adenocarcinomas or squamous carcinomas is not fully understood, also due to the heterogeneity of diagnostic criteria for this tumor entity.
  • On the basis of gene expression profiling data, reporting a remarkable differential expression of desmocollin-3 (a protein localized in desmosomal junctions of stratified epithelial) between adeno- and squamous cancers, we immunostained 62 cases of resected undifferentiated large-cell lung carcinomas for desmocollin-3 (and for TTF-1, p63 and mucin stain), to test its ability to identify a (residual) squamous phenotype, if present.
  • Desmocollin-3 was expressed in almost half of the undifferentiated large-cell cancers and was mutually exclusive with TTF-1 (positive in 39%; the remaining 18 % of cases was double negative).
  • Special large-cell carcinoma variants expressed desmocollin-3 in 6 of 6 basaloid, 7 of 12 clear-cell types, again mutually exclusive with TTF-1 expression.
  • In 31 cytological samples diagnosed as 'non-small-cell lung carcinoma', desmocollin-3 was again mutually exclusive with TTF-1 and stained all squamous carcinomas, 1 of 19 adenocarcinoma only, and 50% of large-cell carcinoma (all histologically confirmed).
  • This combined morphophenotypic approach may represent a valid adjunct (for both surgical and cytological samples) in the selection of patients with lung cancer to medical treatments tailored according to different efficacy in different lung carcinomas of the squamous, adeno- and large-cell types.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Desmocollins / biosynthesis. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287461.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / DSC3 protein, human; 0 / Desmocollins; 0 / TTF1 protein, human
  •  go-up   go-down


62. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827584.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


63. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Gawrychowski J, Bruliński K, Malinowski E, Papla B: Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg; 2005 Apr;27(4):686-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and survival after radical resection of primary adenosquamous lung carcinoma.
  • OBJECTIVE: In order to evaluate the follow-up study of surgical treatment for primary adenosquamous lung carcinoma (ASC) we specified prognostic criteria, also in comparison with primary adenocarcinoma (AC).
  • CONCLUSIONS: Our findings indicate that in patients after radical operation for ASC, predominance for one of the histopathological components (adenous or squamous) within primary tumor is attended by worst prognosis.
  • Our study confirmed also that the prognosis of ASC of the lung was poorer than that of primary AC.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Cause of Death. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784375.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao J, Cao W, Cozen W, Mack TM, Zhang ZF: Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus. Int J Cancer; 2006 Feb 1;118(3):714-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus.
  • We investigated the effects of XPG His1104Asp polymorphism (rs17655) on the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus (SCCOLE).
  • This population-based case-control study involves 611 new cases of lung cancer, 601 new cases of oropharyngeal, laryngeal and esophageal cancers, and 1,040 cancer-free controls.
  • The XPG polymorphism was assayed by PCR-RFLP method for 497 lung cancer cases, 443 cases of oropharyngeal, laryngeal and esophageal cancers and 912 controls.
  • With the adjustment for potential confounders, the XPG Asp1104Asp genotype was inversely associated with lung cancer (odds ratio [OR] = 0.62, 95% confidence limits [CL] = 0.38, 1.0) and SCCOLE (OR = 0.47, 95% CL = 0.27, 0.82), with the combined His1104His and His1104Asp genotypes as the referent.
  • With subjects having genotype Asp1104Asp and no tobacco smoking exposure as the common referent, the ORs on lung cancer were 13 (95% CL = 4.4, 37) for heavy tobacco smoking (>20 pack-years), 1.9 (95% CL = 0.78, 4.5) for having at least one copy of 1104His, and 23 (95% CL = 9.5, 56) for the joint effect, respectively.
  • Compared to non-smokers with the Asp1104Asp genotype, the adjusted OR on SCCOLE for heavy smokers (>20 pack-years) having at least one copy of 1104His was 8.0 (95% CL = 2.7, 24).
  • Similarly, compared to non-drinkers with the Asp1104Asp genotype, the adjusted OR on SCCOLE for heavy drinkers (> or =3 drinks/day) with at least one copy of 1104His was 10 (95% CL = 2.7, 38).
  • In conclusion, our study suggests that the XPG Asp1104Asp genotype may be associated with decreased susceptibility to lung cancer and SCCOLE.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA-Binding Proteins / genetics. Endonucleases / genetics. Esophageal Neoplasms / genetics. Laryngeal Neoplasms / genetics. Lung Neoplasms / etiology. Nuclear Proteins / genetics. Oropharyngeal Neoplasms / genetics. Polymorphism, Genetic. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adolescent. Adult. Alcohol Drinking. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / genetics. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Case-Control Studies. DNA Repair. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Odds Ratio. Polymerase Chain Reaction. Prognosis. Risk Factors. Tobacco

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16094634.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09142; United States / NCI NIH HHS / CA / CA77954; United States / NCI NIH HHS / CA / CA90833; United States / NCI NIH HHS / CA / CA96134; United States / NIDA NIH HHS / DA / DA11386; United States / NIEHS NIH HHS / ES / ES 011667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA excision repair protein ERCC-5; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; EC 3.1.- / Endonucleases
  •  go-up   go-down


66. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR: Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res; 2010 Apr 15;16(8):2466-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.
  • PURPOSE: We have shown the feasibility of administering inhaled doxorubicin to patients with cancer.
  • This study evaluated inhaled doxorubicin combined with cisplatin and docetaxel in patients with non-small cell lung cancer.
  • EXPERIMENTAL DESIGN: Patients who had chemo-naïve advanced non-small cell lung cancer were enrolled in the study.
  • Escalation was permitted if < or =2 of 6 patients experienced pulmonary dose-limiting toxicity (grade 2 Radiation Therapy Oncology Group lung morbidity; resting O(2) saturation of <85%; decrease in diffusing capacity for carbon monoxide, forced vital capacity, or forced expiratory volume in 1 second of > or =20% from baseline or < or =30% of predicted; or grade 3 Common Terminology Criteria for Adverse Events version 3.0 pulmonary toxicity).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371682.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS646368; NLM/ PMC4262532
  •  go-up   go-down


67. Caimmi PP, Di Biasi P: Combined minimally invasive coronary bypass surgery and left pulmonary lobectomy. Asian Cardiovasc Thorac Ann; 2006 Jun;14(3):250-1
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined minimally invasive coronary bypass surgery and left pulmonary lobectomy.
  • Two patients underwent combined heart and lung surgery performed through a limited left anterior thoracotomy.
  • Good exposure of the left pulmonary hilum and the left anterior descending artery was obtained, allowing left upper lobectomy combined with off-pump coronary bypass grafting.
  • These cases show that a limited thoracotomy allows safe and effective combined lung and cardiac surgery in carefully selected patients.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Coronary Artery Bypass, Off-Pump. Coronary Stenosis / surgery. Lung Neoplasms / surgery. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Asian Cardiovasc Thorac Ann. 2006 Dec;14(6):537-8 [17130338.001]
  • (PMID = 16714707.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Shen H, Yuan Y, Sun J, Gao W, Shu YQ: Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother; 2010 Feb;64(2):88-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
  • Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is approved for clinical use in the treatment of non-small cell lung cancer (NSCLC).
  • According to statistics, NSCLC patients who are female, have adenocarcinoma, or never smoked have a higher response rate to gefitinib treatment.
  • To test whether inhibition of the EGFR signaling pathway affects the antitumour effect of gefitinib, NSCLC cell lines were treated with gefitinib and tamoxifen, an ER antagonist.
  • Cotreatment with gefitinib plus tamoxifen decreased the proliferation and increased the apoptosis of A549 and H1650 adencarcinoma cell lines, when compared with either drug alone.
  • However, there was no effect on H520 cells (squamous cell carcinoma).
  • These results suggest that there is a functional cross-signaling between the EGFR and the ER pathways in NSCLC, possibly providing a rationale to combine gefitinib with anti-estrogen therapy for lung cancer treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Cell Proliferation / drug effects. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Quinazolines / pharmacology. Tamoxifen / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Drug Screening Assays, Antitumor. Estrogen Receptor beta / antagonists & inhibitors. Estrogen Receptor beta / metabolism. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Receptor Cross-Talk. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20005069.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Estrogen Receptor beta; 0 / Quinazolines; 094ZI81Y45 / Tamoxifen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


69. Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, Stathopoulos J, Provata A, Yiamboudakis P, Veldekis D, Lolis N, Georgatou N, Toubis M, Pappas Ch, Tsoukalas G: Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol; 2010 Nov;21(11):2227-32
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial.
  • PATIENTS AND METHODS: Two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell lung cancer were randomly allocated to receive either 200 mg/m² of liposomal cisplatin and 135 mg/m² paclitaxel (arm A) or 75 mg/m² cisplatin and 135 mg/m² paclitaxel (arm B), once every 2 weeks on an outpatient basis.
  • CONCLUSIONS: Liposomal cisplatin in combination with paclitaxel has been shown to be much less toxic than the original cisplatin combined with paclitaxel.


70. Kang HG, Chae MH, Park JM, Kim EJ, Park JH, Kam S, Cha SI, Kim CH, Park RW, Park SH, Kim YL, Kim IS, Jung TH, Park JY: Polymorphisms in TGF-beta1 gene and the risk of lung cancer. Lung Cancer; 2006 Apr;52(1):1-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in TGF-beta1 gene and the risk of lung cancer.
  • BACKGROUND: Transforming growth factor-beta1 (TGF-beta1) functions as a suppressor of tumor initiation by inhibiting cellular proliferation or by promoting cellular differentiation or apoptosis in the early phase of cancer development.
  • Variations in the DNA sequence in the TGF-beta1 gene may lead to altered TGF-beta1 production and/or activity, and so this can modulate an individual's susceptibility to lung cancer.
  • To test this hypothesis, we investigated the association of the TGF-beta1 -509C > T and 869T > C (L10P) polymorphisms and their haplotypes with the risk of lung cancer in a Korean population.
  • METHODS: The TGF-beta1 genotypes were determined in 432 lung cancer patients and in 432 healthy control subjects who were frequency-matched for age and gender.
  • RESULTS: Individuals with at least one -509T allele were at a significantly decreased risk of adenocarcinoma (AC) and small cell carcinoma (SM), as compared with carriers with the -509CC genotype [adjusted odds ratio (OR), 0.63; 95% confidence interval (CI), 0.42-0.96; P = 0.04; and adjusted OR, 0.45; 95% CI, 0.27-0.76; P = 0.002; respectively].
  • For the 869T > C polymorphism, the combined TC + CC genotype was associated with a significantly decreased risk of SM compared with the TT genotype (adjusted OR, 0.52; 95% CI, 0.31-0.88; P = 0.01).
  • CONCLUSION: The TGF-beta1 -509C > T and 869T > C polymorphisms and their haplotypes may contribute to genetic susceptibility to AC and SM of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Small Cell / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic. Transforming Growth Factor beta / genetics
  • [MeSH-minor] Carcinoma, Large Cell / genetics. Carcinoma, Squamous Cell / genetics. Case-Control Studies. Female. Genetic Predisposition to Disease. Haplotypes. Humans. Male. Middle Aged. Risk Factors. Transforming Growth Factor beta1

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499994.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


71. Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, Chung DH, Goo JM, Park CM, Lee CH, Kang KW: Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol; 2010 Apr;5(4):497-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
  • INTRODUCTION: The purpose of this study was to assess the value of tumor response evaluation using combined interpretation of [18F] fluorodeoxyglucose positron emission tomography (PET) and computed tomography (CT) for the prediction of clinical outcome and pathologic response in patients with stage III non-small cell lung cancer who underwent neoadjuvant chemotherapy followed by surgery.
  • Forty-four consecutive patients (M:F = 32:12; mean age, 60.7 years) with locally advanced non-small cell lung cancer received neoadjuvant chemotherapy followed by curative surgery.
  • CONCLUSIONS: Tumor response evaluation using combined interpretation of [18F] fluorodeoxyglucose-PET and CT was more effective than single interpretation of CT response or PET response alone for the prediction of tumor recurrence and pathologic response.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Neoadjuvant Therapy. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiography. Carcinoma, Large Cell / radionuclide imaging. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Combined Modality Therapy. Disease Progression. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging. Radiopharmaceuticals. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome


72. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer; 2006 Jan;51(1):31-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma.
  • Specifically, a nuclear, opposed to a combined nuclear and cytoplasmic localization has been associated with increased survival in human malignancies, including non-small cell lung cancer (NSCLC).
  • However, it is not known whether transformation affects maspin expression during lung carcinogenesis, and whether its subcellular localization correlates with the morphological features of NSCLC.
  • Immunohistochemistry revealed maspin expression to be virtually universal in NSCLC, occurring in 72/77 Adenocarcinoma (ACa), and 46/46 squamous cell carcinoma (SqCCa).
  • SqCCa showed almost exclusively a combined nuclear-cytosolic stain.
  • In contrast, nuclear maspin, but not combined nuclear-cytoplasmic maspin significantly correlated with low histological grade, lower proliferative rate, absence of invasion, and negative p53 stain in ACa.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Nucleus / metabolism. Lung Neoplasms / metabolism. Serine Proteinase Inhibitors / pharmacokinetics. Serpins / pharmacokinetics
  • [MeSH-minor] Blotting, Western. Bronchi / drug effects. Bronchi / metabolism. Bronchi / pathology. Cell Line, Tumor. Cytoplasm / metabolism. Genes, Tumor Suppressor. Humans. Immunohistochemistry. In Vitro Techniques

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16159682.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


73. Nagano H, Yoshifuku K, Deguchi K, Kurono Y: Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report. Auris Nasus Larynx; 2010 Apr;37(2):238-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
  • Malignant tumors in the paranasal sinuses and nasal cavity are mostly squamous cell carcinomas, with comparatively few adenocarcinomas.
  • Adenocarcinoma developing in paranasal sinuses and nasal cavity generally has a low response to radiotherapy and low chemotherapeutic sensitivity, making surgery the most reliable treatment.
  • However, advanced adenocarcinoma is often difficult to treat due to anatomical complexity, and the outcome may not be satisfactory.
  • Adenocarcinoma was diagnosed by open biopsy.
  • However, the tumor enlarged and developed distant metastasis to the lung after this therapy.
  • The patient is alive after a follow-up period of 43 months, indicating that TPF chemotherapy may be useful for adenocarcinoma of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Nose Neoplasms / drug therapy. Paranasal Sinus Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19560300.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, Santos ES, Lopes G, Raez LE: Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol; 2010 Apr;5(4):533-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
  • INTRODUCTION: In 2003, consolidation docetaxel was a promising concept for unresectable stage IIIA/B nonsmall cell lung cancer (NSCLC).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Radiotherapy Dosage
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carboplatin / administration & dosage. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357618.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


75. Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A: First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer Ther; 2009 Apr;9(4):425-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.
  • Lung cancer is the leading cause of cancer mortality worldwide.
  • However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Bevacizumab. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Management. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Immunoglobulins, Intravenous. Multicenter Studies as Topic. Organoplatinum Compounds / administration & dosage. Palliative Care. Pemetrexed. Randomized Controlled Trials as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374597.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 0 / Glutamates; 0 / Immunoglobulins, Intravenous; 0 / Organoplatinum Compounds; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; VE267FC2UB / figitumumab
  • [Number-of-references] 73
  •  go-up   go-down


76. Poettgen C, Theegarten D, Eberhardt W, Levegruen S, Gauler T, Krbek T, Stamatis G, Teschler H, Kuehl H, Bockisch A, Stuschke M: Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology; 2007;73(5-6):316-23
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.
  • METHODS: (18)F-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/45 Gy).
  • RESULTS: Sixty patients [40 male/20 female, median age 56 years (34-78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected.
  • SUV(mean) was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18497503.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


77. Lin L, Hao X, Li J, Wang Z, Wang Y, Wang H, Hu X, Zhang X: [Clinical report of combined chemotherapy with gemcitabine plus cisplatin as first-line treatment to 79 cases of advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Dec 20;10(6):513-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical report of combined chemotherapy with gemcitabine plus cisplatin as first-line treatment to 79 cases of advanced non-small cell lung cancer].
  • BACKGROUND: Chemotherapy is the main treatment measure of advanced non-small cell lung cancer(NSCLC).The aim of this study is to explore the efficacy,toxicity,time to disease progression(TTP) and overall survival under the combined chemotherapy with gemcitabine(GEM) plus cisplatin(DDP) in the treatment of advanced NSCLC.
  • METHODS: Retrospective review was conducted on 79 chemotherapy-naive cases of advanced NSCLC treated with GEM and DDP from October 1999 to November 2005.Among 79 patients,51 were male and 28 female;the median age was 53 years old(ranged from 21 to 74);there were 17 cases of squamous cell carcinoma,53 cases of adenocarcinoma,3 cases of large cell carcinoma,1 case of adeno-sqamous cell carcinoma,5 unidentified cases;there were 26 cases in IIIB stage and 53 cases in IV stage according to AJCC 1997 standard.All patients received GEM 800-1250 mg/m² on days 1 and 8 and DDP 75-80 mg/m² on day 1 or 30 mg/m² for three days by intravenous administration,with 21 days as one cycle.Each patient received 2-4 cycles chemotherapy.
  • CONCLUSIONS: Combined chemotherapy with GEM plus DDP as first-line treatment to advanced NSCLC is an effective and feasible regimen,which is one of the standard regimens.For old patients,this regimen is a good choice.The fit dosage of GEM for Chinese is 1000 mg/m².

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129311.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z, Guo C: Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer. Ann Surg Oncol; 2007 Dec;14(12):3581-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
  • BACKGROUND: We sought to investigate the prognostic significance of nuclear factor (NF)-kappaB activity, especially nuclear RelA and IkappaB-alpha expression patterns, in non-small cell lung cancer (NSCLC).
  • Expression of nuclear RelA/NF-kappaB showed an increase in NSCLC tissue compared with adjacent normal tissue and normal lung tissue.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Gene Expression Regulation, Neoplastic. I-kappa B Proteins / metabolism. Lung Neoplasms / metabolism. NF-kappa B / metabolism. Transcription Factor RelA / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Apoptosis. Blotting, Western. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Cell Nucleus / metabolism. Cytoplasm / metabolism. Electrophoretic Mobility Shift Assay. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Interleukin-8 / genetics. Interleukin-8 / metabolism. Male. Middle Aged. Prognosis. Survival Rate. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899287.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / I-kappa B Proteins; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Transcription Factor RelA; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 139874-52-5 / NF-kappaB inhibitor alpha
  •  go-up   go-down


79. Imakiire T, Koike T, Watanabe T, Saito Y, Hirono T: [Lung cancer combined with idiopathic interstitial pneumonias]. Kyobu Geka; 2005 Jan;58(1):4-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer combined with idiopathic interstitial pneumonias].
  • It is known that patients with idiopathic interstitial pneumonias (IIPs) have an increased incidence of lung cancer.
  • The purpose of this study was to evaluate the outcome of surgical treatment and to establish the surgical strategy for lung cancer with IIPs.
  • Twenty-five patients with lung cancer and IIPs who were admitted in our hospital from 1996 to 2004 were examined.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Diseases, Interstitial / complications. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymph Node Excision. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15678958.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


80. Villanueva-Herraiz S, Ortega-García MP, Camps-Herrero C, Blasco-Segura P: [Study of use of pemetrexed in non-small cell lung cancer]. Farm Hosp; 2010 Jul-Aug;34(4):194-203
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of use of pemetrexed in non-small cell lung cancer].
  • [Transliterated title] Estudio de utilización de pemetrexed en el cáncer de pulmón no microcítico.
  • OBJECTIVE: To study the effectiveness and safety of pemetrexed in non-small cell lung cancer.
  • RESULTS: The study included 44 patients (61.7 [39-77] years old), mostly male (86%), smokers or former smokers (80%) with predominantly epidermoid/squamous disease (46%) or adenocarcinoma, in a good functional state (86%) and in stage > or =III upon beginning pemetrexed treatment (93%).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Drug Evaluation. Female. Hospital Records / statistics & numerical data. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Oncology Service, Hospital / statistics & numerical data. Pemetrexed. Pharmacy Service, Hospital / statistics & numerical data. Retrospective Studies. Smoking / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 SEFH. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20594885.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


81. Chhajed PN, Baty F, Pless M, Somandin S, Tamm M, Brutsche MH: Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. Chest; 2006 Dec;130(6):1803-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
  • OBJECTIVE: In patients with advanced non-small cell lung cancer (NSCLC) treated with chemotherapy, we compared survival in patients with treated central airway obstruction to those who did not have central airway obstruction.
  • There was no influence of the histologic subtype on survival in both groups combined and also in each group separately.
  • [MeSH-major] Airway Obstruction / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Aged. Bronchoscopy. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Laser Therapy. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care. Radiotherapy, Adjuvant. Stents. Survival Analysis


82. Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA: The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol; 2008 Feb;3(2):145-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
  • Patients with resected non-small cell lung cancer, a good functional status, and preserved organ function were eligible.
  • RESULTS: Seventy-two patients were treated, and the patient demographics were: median age 65 years (range 47-84), gender male/female 67%/33%, stage I (40%), II (36%) IIIA (22%) and IIIB (1%), and the two most common histologies were: adenocarcinoma (44%), and squamous cell carcinoma (42%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303435.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


83. Zhang X, Li TR, Chen ZS, Ouyang XN: [Comparing serum tumor antigen detection combined with CT scan with PET-CT for lung cancer diagnosis]. Ai Zheng; 2006 Jan;25(1):66-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparing serum tumor antigen detection combined with CT scan with PET-CT for lung cancer diagnosis].
  • BACKGROUND & OBJECTIVE: Positron emission tomography-computed tomography (PET-CT) is a new bio-imaging system which combined metabolic with anatomic imaging.
  • This study was to compare the accuracy of tumor antigen detection combined with CT scan with PET-CT for lung cancer diagnosis and staging.
  • METHODS: A total of 43 lung cancer patients diagnosed by operation or acupuncture, received breast CT scan, tumor antigen detection, and PET-CT scan, were selected.
  • The accuracies of these 2 methods and their impacts on lung cancer staging were compared.
  • RESULTS: The accurate diagnosis rate of tumor antigen detection combined with CT scan was 67.44%, and that of PET-CT scan was 90.70%.
  • PET-CT detected 6 cases of distant metastasis which were not detected by tumor antigen detection combined with CT scan.
  • CONCLUSION: Compare with tumor antigen detection combined with CT scan, PET-CT scan is more sensitive and accurate in diagnosing and staging lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / blood. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / immunology. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405752.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


84. Koumarianou A, Fountzilas G, Kosmidis P, Klouvas G, Samantas E, Kalofonos C, Pentheroudakis G, Economopoulos T, Pectasides D: Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients. J Chemother; 2009 Nov;21(5):573-83
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.
  • It is controversial whether non-small cell lung cancer (NSCLC) in the elderly constitutes a distinct clinico-biological entity compared to younger counterparts.
  • Records were abstracted from the Hellenic Cooperative Oncology Group (HeCOG) cancer registry database.
  • Elderly patients differed significantly in terms of presence of symptoms (p<0.001), including thoracic pain (p=0.003), dyspnea (p<0.001), cough (p<0.001) and fatigue (p<0.001), eastern Cooperative Oncology Group performance status (PS) 2-3 (p<0.001), and histological type (more commonly diagnosed with squamous cell carcinoma (p<0.002) and less frequently with adenocarcinoma).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / therapy. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Age Factors. Aged. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Registries. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933050.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


85. Tanai C, Yamamoto N, Ohe Y, Takahashi T, Kunitoh H, Murakami H, Yamamoto N, Nakamura Y, Nokihara H, Shukuya T, Baldwin JR, Koshiji M, Tamura T: A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. J Thorac Oncol; 2010 Jul;5(7):1068-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
  • We conducted this phase I study to evaluate the safety, pharmacokinetics, and clinical activity of this combination in patients with previously treated advanced non-small cell lung cancer.
  • CONCLUSIONS: Both schedules of enzastaurin in combination with pemetrexed were well tolerated and clinically active in patients with advanced non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453691.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 0 / Indoles; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; UC96G28EQF / enzastaurin
  •  go-up   go-down


86. Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF: Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol; 2010 Mar;5(3):354-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
  • INTRODUCTION: Bevacizumab (B) improves survival of patients with metastatic, nonsquamous non-small cell lung cancer.
  • Based on encouraging results from preclinical studies combining B with sunitinib (S), a phase II, randomized, open-label study (Study Assessing the Blockade of both VEGF Receptor and ligand to enhance Efficacy in Lung) was initiated to assess clinical outcomes of adding S to paclitaxel (P)/carboplatin (C) + B (PCB) for first-line treatment of locally advanced, metastatic, or recurrent nonsquamous non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032789.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


87. Mizutani H, Gemma A: [Lung cancer]. Gan To Kagaku Ryoho; 2009 Feb;36(2):171-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer].
  • In the treatment of lung cancer, the standard for treatment selection is to make the important classification of small cell lung cancer(SCLC)and non-small cell lung cancer(NSCLC).
  • Thus, treatment must be chosen in terms of the presence or absence of adenocarcinoma, an ethnic group, gender, a smoking history, and also the gene mutation.
  • Moreover, it was reported by ASCO in 2008 that efficacy of pemetrexed is low for non-squamous cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / classification. Lung Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223731.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Zhang Z, Xu F, Wang S, Li N, Wang C: Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer. Lung Cancer; 2008 Jun;60(3):434-40
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.
  • BACKGROUND: Numerous studies indicate that smoking is associated with many factors that contribute to poorer outcomes in patients with lung cancer and may limit the efficacy of treatment, especially in advanced non-small cell lung cancer (NSCLC), but little is known about its effect on treatment of resected NSCLC.
  • Sex, age, tumor location, tumor size, symptoms including hemoptysis, cough, blood in sputum and histologic types were different between smokers and non-smokers.
  • Patients with PY>22.75 were more likely to have squamous cell lung cancer.
  • In non-smokers and patients with PY< or =10, 5-year survival was better for patients receiving adjuvant chemotherapy compared to those without adjuvant chemotherapy, but in patients with PY>10, adjuvant chemotherapy did not have a survival benefit.
  • CONCLUSIONS: A patient with PY>22.75 is more likely to develop squamous cell lung cancer.
  • In non-smokers and patients with PY< or=10, adjuvant chemotherapy has a survival benefit.
  • [MeSH-major] Adenocarcinoma / physiopathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / physiopathology. Carcinoma, Squamous Cell / physiopathology. Lung Neoplasms / physiopathology. Smoking / physiopathology


89. Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly MS, Komaki R, Liao Z: Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer; 2010 Aug 16;10:431
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
  • BACKGROUND: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer.
  • We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):898-901 [17289883.001]
  • [Cites] J Surg Oncol. 2006 Dec 1;94(7):624-30 [17111394.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1147-55 [17287073.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):62-6 [18172253.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):612-7 [18223238.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):856-62 [18281657.001]
  • [Cites] Mol Carcinog. 2009 Jun;48(6):563-9 [19009560.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3370-8 [19380441.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4680-5 [19584152.001]
  • [Cites] Pharmacogenomics. 2009 Aug;10(8):1277-83 [19663672.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1917-22 [19594543.001]
  • [Cites] Mol Cancer Ther. 2009 Sep;8(9):2496-508 [19755511.001]
  • [Cites] Clin Lung Cancer. 2010 Mar 1;11(2):82-90 [20199973.001]
  • [Cites] Gynecol Oncol. 2010 Apr;117(1):109-16 [20056267.001]
  • [Cites] Pharmacogenomics J. 2011 Jun;11(3):227-36 [20531372.001]
  • [Cites] Cytokine. 2000 Aug;12(8):1232-5 [10930302.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):475-83 [11102890.001]
  • [Cites] J Vasc Res. 2000 Nov-Dec;37(6):443-8 [11146397.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):72-9 [11206229.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):812-6 [12591731.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):452-8 [7844608.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3188-94 [10506617.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):571-5 [15767331.001]
  • [Cites] Lung. 2005 Jan-Feb;183(1):29-42 [15793665.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3647-53 [15897560.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5015-9 [15958542.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1030-6 [17426061.001]
  • (PMID = 20712888.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131274; United States / NIEHS NIH HHS / ES / R01 ES011740; United States / NCI NIH HHS / CA / R01 CA 131274; United States / NCI NIH HHS / CA / P30 CA 16672; United States / NIEHS NIH HHS / ES / R01 ES11740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2939547
  •  go-up   go-down


90. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM, Siegfried JM: Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer; 2009 Apr;64(1):51-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
  • INTRODUCTION: Estrogen receptor beta (ERbeta) has been detected in non-small cell lung cancer (NSCLC) cell lines and tumor specimens.
  • Eight patients had adenocarcinoma, six NSCLC-NOS, four squamous cell, and four BAC.
  • One patient with bronchioalveolar carcinoma (BAC) and a PR had an EGFR L858R mutation in exon 21.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):650-6 [18235126.001]
  • [Cites] Lung Cancer. 2008 Jan;59(1):88-94 [17905466.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):24-33 [10620630.001]
  • [Cites] Lung Cancer. 2000 Dec;30(3):153-60 [11137199.001]
  • [Cites] Endocrinology. 2001 Jul;142(7):2776-88 [11415996.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 13;285(2):340-7 [11444848.001]
  • [Cites] Mol Endocrinol. 2002 Jan;16(1):70-84 [11773440.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40 [11911952.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2141-50 [11929836.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1087-93 [12176788.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3386-95 [12177098.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3396-403 [12177099.001]
  • [Cites] Endocrinology. 2003 Mar;144(3):1032-44 [12586780.001]
  • [Cites] Mol Endocrinol. 2003 Mar;17(3):309-17 [12554774.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):470-8 [12644540.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8542-52 [14612399.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):14-20 [14613022.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6002-11 [14676126.001]
  • [Cites] Lung Cancer. 2004 Jan;43(1):1-5 [14698531.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):826-34 [15173266.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1402-7 [2166143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):21-5 [1986369.001]
  • [Cites] J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):811-4 [2285594.001]
  • [Cites] Am J Epidemiol. 1993 Sep 1;138(5):281-93 [8395141.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):408-14 [8275477.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Apr;20(4):658-66 [10100997.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3317-20 [10416585.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1459-70 [15735034.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1598-605 [15735050.001]
  • [Cites] Chest. 2005 Mar;127(3):768-77 [15764756.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3328-35 [15833866.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):372-81 [15862820.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3212-8 [15886308.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5084-9 [16033821.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Oct;130(4):979-86 [16214508.001]
  • [Cites] Mol Carcinog. 2005 Nov;44(3):202-11 [16010691.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7280-7 [16243798.001]
  • [Cites] Mol Endocrinol. 2005 Nov;19(11):2660-70 [15976008.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):59-63 [16314616.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3340-6 [16785471.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):998-1004 [17047648.001]
  • [Cites] Steroids. 2007 Feb;72(2):135-43 [17276470.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):857-63 [17325698.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):635-47 [17409930.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3413-22 [17545550.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2607-12 [17237237.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L222-8 [17449797.001]
  • [Cites] Oncologist. 2007 Jul;12(7):774-84 [17673609.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4672-6 [17699844.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4743-50 [17909199.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5785-92 [18089876.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2442-9 [18458038.001]
  • (PMID = 18701186.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA9045440; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / K12 CA087716; United States / NCI NIH HHS / CA / P30 CA014520-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Quinazolines; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS107047; NLM/ PMC3164240
  •  go-up   go-down


91. Gould MK, Ghaus SJ, Olsson JK, Schultz EM: Timeliness of care in veterans with non-small cell lung cancer. Chest; 2008 May;133(5):1167-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timeliness of care in veterans with non-small cell lung cancer.
  • BACKGROUND: Timeliness is an important dimension of quality of care for patients with lung cancer.
  • METHODS: We reviewed the records of consecutive patients in whom non-small cell lung cancer (NSCLC) had been diagnosed between January 1, 2002, and December 31, 2003, at the Veterans Affairs Palo Alto Health Care System.
  • RESULTS: We identified 129 veterans with NSCLC (mean age, 67 years; 98% men; 83% white), most of whom had adenocarcinoma (51%) or squamous cell carcinoma (30%).
  • The median time from the initial suspicion of cancer to treatment was 84 days (interquartile range, 38 to 153 days).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Quality Assurance, Health Care / methods. Veterans
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Bronchoscopy. California / epidemiology. Combined Modality Therapy / methods. Confidence Intervals. Female. Follow-Up Studies. Humans. Male. Mediastinoscopy. Neoplasm Staging / methods. Odds Ratio. Radiography, Thoracic. Retrospective Studies. Survival Rate. Time Factors. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed


92. Balcer-Kubiczek EK, Attarpour M, Edelman MJ: The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines. Cancer Chemother Pharmacol; 2007 May;59(6):781-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.
  • BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cell cycle progression in non-small cell lung cancer (NSCLC) cell lines.
  • METHODS: Asynchronous cultures of three NSCLC (phenotype) lines, A549 (adenocarcinoma), NCI-H226 (squamous) and NCI-H596 (adenosquamous) were used.
  • Cells were treated for 24 h with BPU at various concentrations (0-10 microM) to obtain drug doses for inhibiting cell survival by approximately 50% (IC50).
  • Cell survival was determined by a colony-forming ability assay.
  • The effect of BPU on the cell cycle distribution and induction of apoptosis were measured by flow cytometry-based assays.
  • RESULTS: BPU (1.5 microM) for 24 h produced approximately 50% cell survival.
  • BPU and X-irradiation were synergistic in the three cell lines at survival levels of 20-50%.
  • Flow cytometry analysis of replicate experiments with BPU (1.5 microM for 24 h) showed that BPU blocked cell progression at S and/or G2/M.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Methylurea Compounds / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Survival / drug effects. Combined Modality Therapy. DNA Damage / drug effects. Humans. Radiation-Sensitizing Agents / therapeutic use. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957930.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Methylurea Compounds; 0 / Radiation-Sensitizing Agents; 0 / dimethyl benzoylphenyl urea
  •  go-up   go-down


93. Terashima T, Matsuzaki T, Ogawa R, Naitou A, Morishita T, Ishizaka A: [Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2008 Jul;46(7):516-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer].
  • The efficacy and toxicity of treatment with carboplatin (AUC= 5)+ docetaxel (70mg/m2) were analyzed retrospectively in 27 elderly patients with advanced non-small-cell lung cancer (NSCLC) aged 70 years or more.
  • The performance status (ECOG), clinical stage, and tumor histology in the patients were as follows: PS: PS 0, 12 patients; PS 1, 11 patients; PS 2, 4 patients; disease stage: stage IIIA, 5 patients; stage IIIB, 11 patients; stage IV, 11 patients; tumor histology: adenocarcinoma, 18 patients; squamous cell carcinoma, 9 patients.
  • Prospective studies comparing carboplatin + docetaxel with third-generation single-agent chemotherapy or non-platinum-based combination chemotherapy are needed to confirm the efficacy and safety of this drug combination.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700567.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


94. Zhao ZL, Song N, Huang QY, Liu YP, Zhao HR: [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases]. Ai Zheng; 2007 Feb;26(2):183-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases].
  • BACKGROUND & OBJECTIVE: Lung pleomorphic (spindle/giant cell) carcinoma is a rare epithelial malignant tumor.
  • METHODS: Clinicopathologic records of 17 patients with lung pleomorphic (spindle/giant cell) carcinoma were reviewed and compared with those of the patients with other histopathologic types of lung cancer treated in the same period.
  • Of the 17 cases of lung pleomorphic (spindle/giant cell) carcinoma, 2 were lung exclusive spindle cell carcinoma, 5 were lung carcinoma with spindle cells (combined with one kind of epithelial components, such as squamous cell carcinoma in 3 cases, adenocarcinoma in 1 case, and large cell carcinoma in 1 case), 10 were lung carcinoma with giant cell carcinoma (combined with one kind of epithelial components in 5 cases, two kinds in another 5 cases).
  • The median survival time was significantly shorter in lung pleomorphic (spindle/giant cell) carcinoma patients than in lung squamous cell carcinoma patients (36 months vs. 61 months, P=0.027), and was also significantly longer in patients with carcinoma containing spindle cells (including spindle cell carcinoma) than in patients with carcinoma containing giant cells (64 months vs. 18 months,P=0.026).
  • Lymph node metastasis and carcinoma containing giant cells were poor prognostic factors of lung pleomorphic (spindle/giant cell) carcinoma.
  • CONCLUSION: Lung carcinoma containing giant cells has multiple cells components, and has worse prognosis than lung carcinoma containing spindle cells and spindle cells carcinoma do.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298750.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Weiss J, Eaby B, Stevenson J, Kucharczuk J, Cooper J, Kaiser L, Shrager J, Rengan R, Langer C, Evans T: Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience. J Thorac Oncol; 2010 May;5(5):667-72
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience.
  • INTRODUCTION: Cisplatin and docetaxel (Doc) are commonly used for adjuvant therapy for non-small cell lung cancer based on extrapolation from the metastatic setting.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20234321.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Heigener DF, Reck M, Gatzemeier U: [Non-small cell lung cancer - diagnostics and stage-adapted therapy]. Med Klin (Munich); 2007 Dec 15;102(12):981-8; quiz 989-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-small cell lung cancer - diagnostics and stage-adapted therapy].
  • [Transliterated title] Nichtkleinzelliges Lungenkarzinom - Diagnostik und stadienadaptierte Therapie.
  • Non-small cell lung cancer is a common disease.
  • Adeno- and squamous-cell type are the most frequent subtypes, the former with rising incidence.
  • Stage I disease is a domain of surgery, in stage II combined with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Non-Small-Cell Lung. Carcinoma, Squamous Cell. Lung Neoplasms
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Bronchoscopy. Chemotherapy, Adjuvant. Humans. Lung / pathology. Lymphatic Metastasis. Magnetic Resonance Imaging. Meta-Analysis as Topic. Neoplasm Staging. Positron-Emission Tomography. Radiography, Thoracic. Radiotherapy, Adjuvant. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075718.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


97. Yi SZ, Zhang DC, Wang YG, Sun KL: [Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases]. Ai Zheng; 2006 Jun;25(6):731-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases].
  • BACKGROUND & OBJECTIVE: Along with the progress of tumor diagnosis, the detection of multiple primary tumors (MPT) of the lung combined with other organs is increasing, but their clinical features and prognosis are unclear yet.
  • This study was to investigate clinical features and prognosis of MPT of the lung combined with other organs.
  • METHODS: Of the 281 patients with MPT of the lung combined with other organs, treated in our hospital from Jan.
  • 1990 to Dec. 2000, 115 had lung cancer diagnosed first (Group A), 116 had other cancers diagnosed first (Group B).
  • At the diagnosis of the first cancer of MPT, the median age of the patients was significantly older in Group A than in Group B (62.5 years vs. 54.5 years, P=0.02), while at the diagnosis of the second cancer, it showed no significant difference between the 2 groups (64.5 years vs. 63.5 years, P=0.08).
  • The proportion of stage I-II lung cancer was significantly higher in Group A than in Group B (83.9% vs. 63.7%, P<0.01).
  • Since the diagnosis of first primary cancer, the medium survival time was shorter in Group A than in Group B (69.0 months vs. 87.5 months), and the 5-year survival rate was significantly lower in Group A than in Group B (59.0% vs. 70.0%, P<0.001).
  • Since the diagnosis of second primary cancer, no significant difference in medium survival time and 5-year survival rate was observed between the two groups (25.0 months vs. 28.0 months, 10.5% vs. 13.5%, P=0.92).
  • Second primary cancers occurred in the lung, upper respiratory tract, breast, esophagus, colon, rectum, stomach, and cervix.
  • Smoking was a significant risk factor in the development of MPT of the lung combined with upper respiratory tract.
  • CONCLUSIONS: Lung cancer is closely correlated to upper respiratory tract tumors among MPTs of the lung combined with other organs, and smoking is a potential risk factor.
  • Compared with the patients who had lung cancer diagnosed first, the patients who had other cancers diagnosed first are younger at the first diagnosis, and have longer interval between first and second primary tumors, with better prognosis.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / pathology. Respiratory Tract Neoplasms / surgery. Retrospective Studies. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764770.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Calikusu Z, Yildirim Y, Akcali Z, Sakalli H, Bal N, Ozyilkan O: Prognostic significance of the C-erbB-2 expression in turkish non-small cell lung cancer patients. Asian Pac J Cancer Prev; 2009 Jul-Sep;10(3):479-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the C-erbB-2 expression in turkish non-small cell lung cancer patients.
  • BACKGROUND: The prognostic value of c-erbB-2 expression in patients with non-small cell lung cancer (NSCLC) remains controversial.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Turkey

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640195.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


99. Dupuy DE, DiPetrillo T, Gandhi S, Ready N, Ng T, Donat W, Mayo-Smith WW: Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest; 2006 Mar;129(3):738-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer.
  • PURPOSES: The standard treatment of stage I non-small cell lung cancer (NSCLC) is surgical resection.
  • Radiofrequency ablation (RFA) is an image-guided, thermally mediated ablative technique recently applied to lung tumors.
  • We report our experience with combined CT-guided RFA and conventional radiotherapy in 24 medically inoperable patients with a minimum of 2-year study follow-up in surviving patients.
  • The histologic subtypes were squamous cell (n = 13), adenocarcinoma (n = 5), and undifferentiated (n = 6).
  • Ten of the deaths were cancer related.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Catheter Ablation. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Conformal. Tomography, X-Ray Computed


100. Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer; 2005 Jul;49(1):85-94
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
  • PURPOSE: To evaluate the efficacy of postoperative adjuvant chemotherapy for completely resected p-stage I non-small cell lung cancer (NSCLC).
  • MATERIALS AND METHODS: Patients who underwent complete resection with lymph node dissection for p-stage I NSCLC (T1N0, T2N0, adenocarcinoma or squamous cell carcinoma, were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949594.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down






Advertisement